Method for analyzing coagulation characteristics of blood specimens

By directly analyzing the waveform parameters related to coagulation speed or coagulation acceleration, the information loss problem caused by smoothing treatment in the prior art is solved, and the accurate assessment of the activity level of coagulation factors is achieved, and the diagnosis and severity assessment of hemophilia is used for the diagnosis and severity of hemophilia .

CN113366319BActive Publication Date: 2024-11-19SEKISUI MEDICAL CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080011260.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-01-31
Filing Date
2020-01-31
Publication Date
2024-11-19
Estimated Expiration
2040-01-31

AI Technical Summary

Technical Problem

The existing coagulation examination methods rely on smoothing treatment to cause the coagulation reaction curve to lose waveform information, unable to accurately reflect the patient's clinical status, and it is difficult to evaluate coagulation factor abnormalities in high-precision.

Method used

By extracting waveform parameters related to coagulation velocity or coagulation acceleration, and analyses to determine the activity level or activity abnormality of coagulation factor are analyzed based on these parameters, smoothing treatment is avoided, and high-precision evaluation is directly used to use non-unimodal curves.

Benefits of technology

Accurate analysis of the activity levels of coagulation factor VIII and FIX is achieved, which is effectively used for the diagnosis and severity assessment of hemophilia, and improves the accuracy and reliability of coagulation examination.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113366319B_ABST
    Figure CN113366319B_ABST
Patent Text Reader

Abstract

The present invention provides a method for analyzing the coagulation characteristics of a blood sample. A method for analyzing a blood sample comprises: obtaining a waveform related to the coagulation rate or coagulation acceleration of a sample obtained by mixing a blood sample to be tested with a coagulation time measuring reagent, extracting a plurality of parameters representing the waveform related to the coagulation rate or coagulation acceleration, and determining the activity level or activity abnormality of a coagulation factor in the blood sample to be tested based on the plurality of parameters.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method for analyzing the coagulation characteristics of a blood sample and also to a program and an apparatus for analyzing the coagulation characteristics of the blood sample. Background Art

[0002] Coagulation test is a test used to investigate the hemostatic ability or fibrinolytic ability of a patient. In a general coagulation test, the coagulation reaction that occurs after adding a reagent to a patient's blood sample is optically measured. The time it takes for coagulation to proceed to a specified state is measured as the coagulation time. Typical examples of coagulation time include prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time, etc. The extension of coagulation time reflects the bleeding tendency in the body. As the causes of the extension, 1) abnormalities in the amount of coagulation factors, 2) the presence of antibodies against blood components that constitute the coagulation system, reagents for coagulation time measurement, etc., 3) the administration of drugs that inhibit coagulation reactions, etc.

[0003] In a coagulation test, a coagulation reaction curve can be obtained by measuring the amount of coagulation reaction after adding a reagent to a blood sample over time. The coagulation reaction curve has different shapes according to the type of abnormality of the coagulation system (non-patent document 1). Therefore, a method for determining the abnormality of the coagulation system based on the coagulation reaction curve is disclosed. For example, Patent Document 1, Patent Document 2 and Patent Document 3 describe a method for evaluating whether the patient has abnormal coagulation factors based on the parameters of the first differential curve and the second differential curve of the coagulation reaction curve of the patient's blood, such as the maximum coagulation rate, the maximum coagulation acceleration and the maximum coagulation deceleration.

[0004] Hemophilia is a disease with congenital deficiency or functional abnormality of coagulation factor VIII (FVIII) or coagulation factor IX (FIX). The activity of normal people is set to 100%, and people with FVIII activity less than 40% are classified as hemophilia A, and people with FIX activity less than 40% are classified as hemophilia B. The severity of hemophilia is further classified according to the activity level. Patent document 4 records that the severity of hemophilia is determined based on the average rate of change of the coagulation speed until the patient's coagulation reaction reaches the maximum coagulation speed or the maximum coagulation acceleration.

[0005] Prior art literature

[0006] Patent Literature

[0007] Patent Document 1: Japanese Patent Application Publication No. 2016-194426

[0008] Patent Document 2: Japanese Patent Application Publication No. 2016-118442

[0009] Patent Document 3: Japanese Patent Application Publication No. 2017-106925

[0010] Patent Document 4: Japanese Patent Application Publication No. 2018-017619

[0011] Non-patent literature

[0012] Non-patent document 1: British Journal of Haematology, 1997, 98: 68-73 Summary of the invention

[0013] The first differential curve of the coagulation reaction curve of an actual blood specimen may not be unimodal depending on the components contained in the specimen, the influence of the reagents used in the test, or the difference in the measurement method. Therefore, in the methods of Patent Documents 1 to 4, in order to accurately determine the parameters such as the maximum coagulation rate and the maximum coagulation rate time, a smoothing process is performed to make the first differential curve unimodal and a waveform analysis is performed. However, it is speculated that when the first differential curve is smoothed to be unimodal in this way, the obtained curve loses waveform information due to the smoothing process, and therefore cannot reflect the clinical status of the patient in detail. Therefore, an analysis method is sought that does not rely on smoothing processing and can evaluate the coagulation characteristics of the specimen with high accuracy even if the first differential curve is not unimodal.

[0014] The present inventors have discovered a parameter from a blood coagulation reaction curve that is correlated with the activity of coagulation factor VIII (FVIII) and coagulation factor IX (FIX). In addition, the present inventors have discovered a method for analyzing the activity level of FVIII or FIX in a blood sample and whether there is abnormal activity of FVIII or FIX in the blood sample based on the parameter.

[0015] Therefore, the present invention provides the following solutions.

[0016] [1] A method for analyzing a blood sample, comprising:

[0017] Acquire a waveform related to the coagulation rate or coagulation acceleration of a sample obtained by mixing the test blood sample and the coagulation time measurement reagent,

[0018] extracting a plurality of parameters characterizing the waveform related to the coagulation rate or coagulation acceleration, and

[0019] The activity level or activity abnormality of the coagulation factor in the test blood sample is determined based on the plurality of parameters.

[0020] 〔2〕The analysis method according to 〔1〕, wherein the plurality of parameters include a plurality of parameters respectively characterizing a plurality of operation object regions of a waveform related to the solidification rate, or include a plurality of parameters respectively characterizing a plurality of operation object regions of a waveform related to the solidification acceleration, or include a combination thereof.

[0021] 〔3〕The analysis method according to 〔2〕, wherein the plurality of parameters include one or more selected from the following parameters:

[0022] The weighted average time vT, weighted average height vH, peak width vB, weighted average peak width vW, B flatness rate vAB of the weighted average height, W flatness rate vAW of the weighted average height, B time rate vTB of the weighted average time, W time rate vTW of the weighted average time, average time vTa, average height vHa, B flatness rate vABa of the average height, W flatness rate vAWa of the average height, region start time vTs, region end time vTe, region central time vTm, region time width vTr, main peak start time vNs, main peak end time vNe, and main peak width vN of a plurality of operation object regions of a waveform related to the solidification rate,

[0023] The weighted average time pT, weighted average height pH, peak width pB, weighted average peak width pW, B flatness rate pAB of the weighted average height, W flatness rate pAW of the weighted average height, B time rate pTB of the weighted average time, W time rate pTW of the weighted average time, main peak start time pNs, main peak end time pNe, and main peak width pN of a plurality of operation object regions of a positive peak of a waveform related to the solidification acceleration, and

[0024] The weighted average time mT, weighted average height mH, peak width mB, weighted average peak width mW, B flatness rate mAB of the weighted average height, W flatness rate mAW of the weighted average height, B time rate mTB of the weighted average time, W time rate mTW of the weighted average time, main peak start time mNs, main peak end time mNe, and main peak width mN of a plurality of operation object regions of a negative peak of a waveform related to the solidification acceleration.

[0025] 〔4〕The analysis method according to 〔3〕, wherein when the waveform related to the solidification rate is set as F(t) (t is time), and the times when F(t) is a specified value x are set as t1, t2 (t1 < t2), the operation object region is a region satisfying F(t) ≥ x, and the vT and vH are represented by the following formulas,

[0026]

[0027]

[0028] here,

[0029]

[0030] F(t), t1 and t2 are defined the same as those of the above F(t), t1 and t2. When the data fraction from F(t1) to F(t2) is set to n, the above vTa, vHa and vTm are respectively expressed by the following formulas:

[0031]

[0032]

[0033]

[0034] vB is the time length from t1 to t2 when F(t)≥x.

[0035] The above vW is the time length from t1 to t2 when F(t)≥vH.

[0036] The above vTs and vTe are t1 and t2 respectively.

[0037] The above vTr is the time length from vTs to vTe,

[0038] vNs is the maximum time of the time that is less than the time when F(t) shows the maximum value and shows F(t)=x in the calculation target area.

[0039] The above-mentioned vNe is the minimum time among the times when F(t)=x and the times when F(t)=x in the calculation target area.

[0040] The above vN is the time length from vNs to vNe,

[0041] The above vAB represents the ratio of vH to vB.

[0042] The above vAW represents the ratio of vH to vW.

[0043] The above vTB represents the ratio of vT to vB.

[0044] The above vTW represents the ratio of the vT to the vW.

[0045] The above vABa represents the ratio of vHa to vB.

[0046] The above-mentioned vAWa represents the ratio of the vHa to the vW.

[0047] 〔5〕The analysis method according to 〔3〕, wherein when the waveform related to the above solidification acceleration is set as F’(t) (t is time), and the times when F’(t) is a specified value x are set as t1 and t2 (t1 < t2), the above operation object region is the region where F’(t) ≥ x, and the above pT and pH are represented by the following formulas,

[0048]

[0049]

[0050] Here,

[0051]

[0052] The above pB is the time length of F’(t) ≥ x from the above t1 to t2,

[0053] The above pW is the time length of F’(t) ≥ pH from the above t1 to t2,

[0054] The above pNs is the maximum time among the times when it is less than the maximum value of F’(t) display in the operation object region and F’(t) = x,

[0055] The above pNe is the minimum time among the times when it is greater than the maximum value of F’(t) display in the operation object region and F’(t) = x,

[0056] The above pN is the time length from pNs to pNe,

[0057] The above pAB represents the ratio of the above pH to the above pB,

[0058] The above pAW represents the ratio of the above pH to the above pW,

[0059] The above pTB represents the ratio of the above pT to the above pB,

[0060] The above pTW represents the ratio of the above pT to the above pW.

[0061] 〔6〕The analysis method according to 〔3〕, wherein when the waveform related to the above solidification acceleration is set as F’(t) (t is time), and the times when F’(t) is a specified value x are set as t1 and t2 (t1 < t2), the above operation object region is the region where F’(t) ≤ x, and the above mT and mH are represented by the following formulas,

[0062]

[0063]

[0064] Here,

[0065]

[0066] mB is the time length from t1 to t2 when F'(t)≤x.

[0067] The above mW is the time length from t1 to t2 when F'(t)≤mH.

[0068] The mNs is the maximum time in the calculation target area, which is less than the time when F'(t) shows the minimum value and shows F'(t) = x.

[0069] The above mNe is the minimum time among the times when F'(t)=x and is greater than the time when F'(t) shows the minimum value in the calculation target area.

[0070] The above mN is the time length from mNs to mNe,

[0071] The above mAB represents the ratio of mH to mB.

[0072] The above mAW represents the ratio of mH to mW.

[0073] The above mTB represents the ratio of mT to mB.

[0074] The above mTW represents the ratio of the mT to the mW.

[0075] [7] An analysis method according to any one of [4] to [6], wherein the specified value x is 0.5 to 99% of the maximum value of the above-mentioned F(t), or 0.5 to 99% of the maximum value of the above-mentioned positive peak of the above-mentioned F'(t), or 0.5 to 99% of the minimum value of the above-mentioned negative peak of the above-mentioned F'(t).

[0076] [8] The analysis method according to any one of [2] to [7], wherein the plurality of operation target regions are 5 to 20 different regions.

[0077] [9] The analysis method according to any one of [1] to [8], wherein the determination comprises:

[0078] comparing the plurality of parameter groups with parameter groups corresponding to a plurality of template blood samples, and,

[0079] determining the activity level or activity abnormality of the coagulation factor in the test blood sample based on the comparison result;

[0080] The template blood sample is a blood sample whose activity level or the presence or absence of activity abnormality of the coagulation factor is known.

[0081]

[10] The analysis method according to [9], wherein the comparison includes obtaining a correlation between the parameter group of the test blood sample and the parameter groups corresponding to the plurality of template blood samples.

[0082]

[11] The analysis method according to

[10] , wherein the determination comprises:

[0083] selecting a template blood sample whose correlation satisfies a specified condition, and

[0084] The activity level or activity abnormality of the coagulation factor in the selected template blood sample is determined as the activity level or activity abnormality of the coagulation factor in the test blood sample.

[0085]

[12] The analysis method according to any one of [1] to

[11] , wherein the coagulation factor is coagulation factor VIII or coagulation factor IX.

[0086]

[13] The analysis method according to

[12] , wherein the determination includes determining a blood sample from the hemophilia A patient.

[0087]

[14] The analysis method according to

[12] , wherein the determination includes determining a blood sample from a patient with severe, moderate or mild hemophilia A.

[0088]

[15] The analysis method according to

[12] , wherein the determination includes determining a blood sample from a patient with extremely severe hemophilia A, moderately severe hemophilia A, moderate hemophilia A, or mild hemophilia A.

[0089]

[16] The analysis method according to

[12] , wherein the determination includes determining a blood sample from the hemophilia B patient.

[0090]

[17] The analysis method according to

[12] , wherein the determination includes determining a blood sample from a patient with severe, moderate or mild hemophilia B.

[0091]

[18] The analysis method according to

[12] , further comprising a second determination step of determining the activity level or activity abnormality of coagulation factor IX in the test blood sample determined to be normal in coagulation factor VIII,

[0092] The second determination step includes:

[0093] comparing the parameter group of the test blood sample with the parameter groups corresponding to a plurality of template blood samples whose activity levels or the presence or absence of activity abnormalities of coagulation factor IX are known, and

[0094] Based on the result of the comparison, the activity level or activity abnormality of the blood coagulation factor IX in the test blood sample is determined.

[0095]

[19] The analysis method according to

[18] , wherein the determination includes determining a blood sample from the hemophilia B patient.

[0096]

[20] The analysis method according to

[18] , wherein the determination includes determining a blood sample from a patient with severe, moderate or mild hemophilia B.

[0097]

[21] A program for performing the blood sample analysis method described in any one of [1] to

[20] .

[0098]

[22] An apparatus for performing the blood sample analysis method described in any one of [1] to

[20] .

[0099] According to the present invention, the activity level of FVIII or FIX in a blood sample or the presence or absence of abnormal activity (deficiency, etc.) can be analyzed based on parameters from a coagulation reaction curve. The present invention is useful for determining hemophilia A or hemophilia B, or determining the severity of hemophilia patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0100] Figure 1 This is one embodiment of the steps of the blood sample analysis method of the present invention.

[0101] Figure 2 yes Figure 1 One embodiment of the steps of the data analysis process is shown.

[0102] Figure 3 is an example of a coagulation reaction curve.

[0103] Figure 4 This is an example of a coagulation reaction curve after pretreatment.

[0104] Figure 5 A in the figure is a partial enlarged view of an example of a coagulation reaction curve. Figure 5 B is a partially enlarged view of an example of a coagulation reaction curve after pretreatment.

[0105] Figure 6 is an example of a calibrated zero-order curve.

[0106] Figure 7 This is an example of a corrected linear curve.

[0107] Figure 8 This is a conceptual diagram of parameters calculated from the waveform related to the coagulation rate.

[0108] Fig. 9 This is a conceptual diagram for explaining the calculation target region value, the range of the correction zero-order curve and the correction first-order curve as the analysis target, and the weighted average score.

[0109] Fig.10 This is a conceptual diagram of the parameters calculated from the quadratic curve.

[0110] Fig.11 It is a conceptual diagram showing vTs, vTe, vTr, vNs, vNe, and vN.

[0111] Fig.12 It is a conceptual diagram showing the weighted average score and vTs, vTe, vB, and vW. The dotted line shows the 10% calculation target area of ​​the first order curve.

[0112] Fig.13 This is a conceptual diagram showing vTa, vHa, and vTm.

[0113] Fig.14 A in the figure is used to explain the weighted average score when the calculation target area value is 10%. Fig.14 B in FIG. 1 is a conceptual diagram for explaining the weighted average score when the calculation target region value is 80%.

[0114] Fig.15 This is a conceptual diagram showing the structure of an automatic analyzer for performing the blood sample analysis method of the present invention.

[0115] Fig.16 It is the regression line of parameter group A-1. The test sample (Sample AF) is from a patient with severe hemophilia A whose FVIII activity is less than 0.2%. In each figure, the horizontal axis and the vertical axis represent the FVIII activity and APTT of the template sample and the test sample, respectively.

[0116] Fig.17 The A in is Fig.16 The regression line of the sample (Template A) with the highest correlation coefficient. Fig.17 B in FIG. 1 is the calibration primary curve of the sample under test (Sample AF) and Template A.

[0117] Fig.18 The distribution of FVIII activity and APTT of the test sample and template sample used in Example 5. A: FVIII activity, B: APTT. Left: test sample, right: template sample.

[0118] Fig.19 This is the influence of the slope tolerance range and correlation coefficient threshold in the regression analysis on the FVIII deficiency consistency rate and the FVIII activity level consistency rate based on judgment criterion 1.

[0119] Fig. 20 This is the influence of the slope tolerance range and correlation coefficient threshold in the regression analysis on the FVIII deficiency consistency rate and the FVIII activity level consistency rate based on judgment criterion 2.

[0120] Fig.21 This is the influence of the slope tolerance range and correlation coefficient threshold in the regression analysis on the FVIII deficiency consistency rate and the FVIII activity level consistency rate based on judgment criterion 3. DETAILED DESCRIPTION

[0121] The present invention relates to analyzing the characteristics associated with blood coagulation of a blood specimen. Hereinafter, a blood specimen is sometimes referred to as a specimen. More specifically, the present invention relates to analyzing the activity level of a blood coagulation time extension factor component in a specimen with prolonged coagulation time or the presence or absence of abnormal activity thereof. Preferably, the present invention relates to analyzing the activity level of blood coagulation factor VIII (hereinafter, also referred to as FVIII) or blood coagulation factor IX (hereinafter, also referred to as FIX) or the presence or absence of abnormal activity thereof. Therefore, one embodiment of the present invention is a method for analyzing a blood specimen, and more specifically, a method for determining the activity level of a blood coagulation time extension factor component, preferably FVIII and / or FIX, or the presence or absence of abnormal activity thereof in a blood specimen. Below, an embodiment of the steps of the method of the present invention is described with reference to the accompanying drawings.

[0122] 1. Analysis method of blood samples

[0123] 1.1. Overview of the Method

[0124] The blood sample analysis method of the present invention (hereinafter also referred to as the method of the present invention) comprises: obtaining a waveform related to the coagulation rate or coagulation acceleration of a sample obtained by mixing a sample to be tested with a coagulation time measuring reagent, extracting a plurality of parameters representing the waveform related to the coagulation rate or coagulation acceleration, and determining the activity level or activity abnormality of a coagulation time prolonging factor component in the sample to be tested based on the plurality of parameters. Figure 1 An embodiment of the method of the present invention is described. In the present method, a sample is first prepared from a test specimen (step 1), and then the coagulation reaction of the sample is measured (step 2). Based on the obtained measurement data, a waveform related to the coagulation rate or coagulation acceleration of the sample is obtained, and then the waveform is analyzed as specified (step 3). Based on the parameters obtained in the analysis, the test specimen is judged (the activity level of the coagulation time prolonging factor component or the activity abnormality thereof) (step 4).

[0125] 1.2. Sample preparation and coagulation reaction measurement

[0126] The preparation of a sample from a test specimen in step 1 and the measurement of a coagulation reaction of the sample in step 2 are described. Here, as a coagulation reaction measurement, the measurement of activated partial thromboplastin time (APTT) is described as an example, and a change to other coagulation reaction measurements (e.g., prothrombin time (PT) measurement) can be implemented by those skilled in the art.

[0127] As an example of the test specimen, there can be cited a specimen from a subject who requires an examination related to coagulation ability, for example, a specimen with coagulation abnormality or a specimen suspected of coagulation abnormality, and more specifically, a specimen with prolonged coagulation time or a specimen suspected of prolonged coagulation time. As the specimen, it is preferred to use plasma from the subject. A known anticoagulant commonly used in coagulation examinations can be added to the specimen. For example, plasma can be obtained by collecting blood using a blood collection tube containing sodium citrate and then centrifuging it.

[0128] The obtained test specimen is mixed with a coagulation time determination reagent to prepare a sample for measuring the coagulation reaction. As an example of the coagulation time determination reagent, any reagent used for APTT determination can be used, for example, activators and phospholipids of the contact factor system can be cited. As examples of activators, ellagic acid, diatomaceous earth, kaolin, silicon dioxide, polyphenol compounds, etc. can be cited. As examples of phospholipids, phospholipids of animal origin, plant origin, and synthetic origin can be cited. As examples of phospholipids of animal origin, phospholipids of rabbit brain origin, chicken origin, and pig origin can be cited. As examples of phospholipids of plant origin, phospholipids of soybean origin can be cited. In addition, a buffer such as Tris hydrochloric acid can be added to the sample as needed. Alternatively, a commercially available APTT determination reagent can be used as the reagent for the APTT determination. As an example of a commercially available APTT determination reagent, COAGPIAAPTT-N (manufactured by Sekisui Medical Co., Ltd.) can be cited. The prepared sample is heated to activate the contact factor in the sample. The temperature during heating is, for example, 30°C to 40°C, or preferably 35°C to 39°C.

[0129] Then, a calcium chloride solution (e.g., COAGPIA APTT-N calcium chloride solution; manufactured by Sekisui Medical Co., Ltd.) is added to the sample containing the test specimen and the coagulation time determination reagent to start the coagulation reaction. The coagulation reaction of the mixed solution after the addition of the calcium chloride solution can be measured. The measurement of the coagulation reaction can be carried out using general methods, such as optical methods for measuring the amount of scattered light, transmittance, absorbance, etc., or mechanical methods for measuring plasma viscosity. The measurement period can be, for example, from tens of seconds to about 5 minutes from the time of addition of the calcium chloride solution. The measurement can be repeated at a predetermined interval between the measurement periods. For example, it is sufficient to measure at intervals of 0.1 seconds. The temperature of the reaction solution during the measurement is, for example, 30°C to 40°C, preferably 35°C to 39°C. The reaction start time of the coagulation reaction can typically be defined as the moment when the calcium chloride solution is added to the sample containing the test specimen, and other times can also be defined as the reaction start time. In addition, various conditions for measurement can be appropriately set according to the test specimen, reagents, measurement methods, etc.

[0130] The series of operations in the above-mentioned coagulation reaction measurement can be performed using an automatic analyzer. As an example of an automatic analyzer, the coagulation automatic analyzer CP3000 (manufactured by Sekisui Medical Co., Ltd.) can be cited. Alternatively, part of the operation can also be performed manually. For example, the preparation of the specimen to be tested can be performed by a person, and the subsequent operations are performed using an automatic analyzer.

[0131] 1.3. Data analysis

[0132] 1.3.1. Primary processing and correction of data

[0133] Next, the data analysis of step 3 is described. The flow of data analysis is shown in Figure 2 The data analysis in step 3 may be performed simultaneously with the coagulation reaction measurement in step 2, or the data analysis in step 3 may be performed subsequently using the coagulation reaction measurement data determined in advance.

[0134] In step 3a, the measurement data in the above-mentioned coagulation reaction measurement is obtained. This data is, for example, data reflecting the coagulation reaction process of the sample obtained in the APTT measurement in step 2. For example, data showing the time change of the amount of coagulation reaction (for example, the amount of scattered light) after the addition of calcium chloride solution is obtained from a sample containing a test specimen and a coagulation time measurement reagent. The data obtained in these coagulation reaction measurements are also referred to as coagulation reaction information in this specification.

[0135] An example of the coagulation reaction information obtained in step 3a is shown in Figure 3 . Figure 3For the coagulation reaction curve based on the scattered light amount, the horizontal axis represents the elapsed time (coagulation reaction time) after the interpolation of calcium chloride solution, and the vertical axis represents the scattered light amount. As time passes, the coagulation reaction of mixed solution is carried out, so the scattered light amount increases. In this manual, the curve of the change of the coagulation reaction amount relative to the coagulation reaction time shown in such scattered light amount etc. is called the coagulation reaction curve.

[0136] like Figure 3 The coagulation reaction curve based on the amount of scattered light shown is usually S-shaped. On the other hand, the coagulation reaction curve based on the amount of transmitted light is usually inverted S-shaped. In the following description, the data analysis using the coagulation reaction curve based on the amount of scattered light as the coagulation reaction information is described. It is obvious to those skilled in the art that the same processing can be performed when the coagulation reaction curve based on the amount of transmitted light and absorbance is used as the data analysis of the coagulation reaction information. Alternatively, the coagulation reaction curve obtained by a mechanical method such as the viscosity change of the mixed solution as the coagulation reaction information can also be used as the analysis object.

[0137] In step 3b, the coagulation reaction curve is pre-processed, which includes smoothing processing and zero point adjustment for removing noise. Figure 4 After pre-processing (smoothing and zero adjustment), Figure 3 An example of a coagulation reaction curve. The smoothing process can use any of the known noise removal methods. Figure 3 As shown in FIG. 1 , the mixed solution containing the sample to be tested originally scatters light, and therefore the amount of scattered light at the start of measurement (time 0) is greater than 0. By adjusting the zero point after smoothing, as shown in FIG. Figure 4 As shown, the amount of scattered light at time 0 is adjusted to 0. Figure 5 A and B in the figure represent before and after pre-processing, respectively. Figure 3 A partial enlarged view of the coagulation reaction curve. Figure 5 B in the middle Figure 5 The data of A in the figure has been smoothed and zero-adjusted.

[0138] The height of the coagulation reaction curve depends on the fibrinogen concentration of the test specimen. On the other hand, since there are individual differences in fibrinogen concentration, the height of the coagulation reaction curve varies depending on the test specimen. Therefore, in this method, as needed, a correction process is performed in step 3c to relative the coagulation reaction curve after pretreatment. Through this correction process, a coagulation reaction curve that does not depend on the fibrinogen concentration can be obtained, thereby making it possible to quantitatively compare the differences in the shapes of the coagulation reaction curves after pretreatment between specimens.

[0139] In one embodiment, in the correction process, the coagulation reaction curve after pre-processing is corrected in such a way that the maximum value reaches a predetermined value. Preferably, in the correction process, the corrected coagulation reaction curve P(t) is obtained from the coagulation reaction curve after pre-processing according to the following formula (1). In formula (1), D(t) represents the coagulation reaction curve after pre-processing, Dmax and Dmin represent the maximum value and minimum value of D(t), respectively, Drange represents the variation range of D(t) (i.e., Dmax-Dmin), and A is an arbitrary value representing the maximum value of the corrected coagulation reaction curve.

[0140] P(t)=[(D(t)-Dmin) / Drange]×A(1)

[0141] As an example, Figure 6 shown in the Figure 4 The coagulation reaction curve shown is the data obtained by correcting the maximum value to 100. Figure 6 In the formula (1), the correction is performed so that the corrected value becomes 0 to 100, but it may be another value (for example, 0 to 10000, that is, A=10000 in the formula (1)). In addition, this correction process may not necessarily be performed.

[0142] Alternatively, the correction process described above may also be performed on the waveform related to the coagulation rate or coagulation acceleration described later or the parameter group extracted from the waveform. For example, the waveform related to the coagulation rate may be calculated for the coagulation reaction curve D(t) after the pre-processing without the correction process, and then converted into a value equivalent to P(t). Alternatively, the parameter group may be extracted from the waveform related to the coagulation rate, and the value of each parameter included in the parameter group may be converted into a value equivalent to P(t).

[0143] In this specification, the corrected coagulation reaction curve and the coagulation reaction curve without correction processing as described above may also be referred to as a corrected zero-order curve and an uncorrected zero-order curve, respectively, and they may also be collectively referred to as a "zero-order curve". In addition, in this specification, the corrected zero-order curve and the first-order differential curve of the uncorrected zero-order curve may also be referred to as a corrected first-order curve and an uncorrected first-order curve, respectively, and they may also be collectively referred to as a "first-order curve". In addition, in this specification, the second-order differential curve of the corrected zero-order curve and the uncorrected zero-order curve or the first-order differential curve of the corrected first-order curve and the uncorrected first-order curve may also be referred to as a corrected second-order curve and an uncorrected second-order curve, respectively, and they may also be collectively referred to as a "secondary curve".

[0144] 1.3.2. Calculation of waveforms related to coagulation rate or coagulation acceleration

[0145] In step 3d, a waveform related to the coagulation speed or coagulation acceleration is calculated. In this specification, the waveform related to the coagulation speed includes an uncorrected first-order curve and a corrected first-order curve. The uncorrected first-order curve represents the value obtained by performing a first differentiation on the coagulation reaction curve (uncorrected 0-order curve), that is, the rate of change (coagulation speed) of the coagulation reaction amount at any coagulation reaction time. The corrected first-order curve represents the value obtained by performing a first differentiation on the corrected coagulation reaction curve (corrected 0-order curve), that is, the relative rate of change of the coagulation reaction amount at any coagulation reaction time. Therefore, the waveform related to the coagulation speed can be a waveform representing the coagulation speed of the coagulation reaction of the sample or its relative value. In this specification, the value of the coagulation process represented by the first-order curve, which includes the coagulation speed and its relative value, is generally referred to as the first-order differential value. In addition, in this specification, the waveform related to the coagulation acceleration includes an uncorrected second-order curve and a corrected second-order curve. In this specification, the value represented by the waveform related to the coagulation acceleration is generally referred to as the second-order differential value. The first and second order differentials of the coagulation reaction curve or the corrected coagulation reaction curve (uncorrected and corrected zero-order curves) can be performed using a known method. Figure 7 Show Figure 6 The corrected 0th order curve shown is differentiated once to obtain a corrected 1st order curve. Figure 7 The horizontal axis represents the coagulation reaction time, and the vertical axis represents the first differential value.

[0146] 1.3.3. Parameter extraction

[0147] In step 3e, multiple parameters characterizing the waveform related to the coagulation rate or coagulation acceleration of the sample are extracted. In one embodiment, the multiple parameters include multiple parameters that respectively characterize the waveform related to the coagulation rate. In another embodiment, the multiple parameters include multiple parameters that respectively characterize the waveform related to the coagulation acceleration. In another embodiment, the multiple parameters that respectively characterize the waveform related to the coagulation rate are used in combination with the multiple parameters that respectively characterize the waveform related to the coagulation acceleration.

[0148] Preferably, in the parameter extraction step of the method of the present invention, multiple operation object areas are extracted from the waveform related to the coagulation rate or the coagulation acceleration, and on the other hand, parameters characterizing the operation object areas are respectively extracted from these multiple operation object areas. As a result, multiple parameters characterizing the multiple operation object areas of the waveform related to the coagulation rate or the coagulation acceleration are extracted. Therefore, the multiple parameters characterizing the waveform related to the coagulation rate or the coagulation acceleration extracted in the present invention include multiple parameters characterizing the multiple operation object areas of the waveform related to the coagulation rate, or include multiple parameters characterizing the multiple operation object areas of the waveform related to the coagulation acceleration, or include a combination thereof. In the method of the present invention, a parameter group including the obtained multiple parameters is prepared. The parameter group reflects the shape of the waveform related to the coagulation rate or the coagulation acceleration, and is associated with the coagulation characteristics of the specimen. The parameter group is used for the determination of the specimen to be tested (step 4). The parameters are described below.

[0149] 1.3.3.2. Extraction of the operation target area

[0150] Regarding the extraction of parameters in the method of the present invention, a step of extracting a plurality of operation target regions from a waveform related to the coagulation rate or the coagulation acceleration will be described.

[0151] Hereinafter, the operation target region and the parameters characterizing the operation target region will be described by taking the waveform related to the coagulation rate as an example. The operation target region is a region (portion) in which the first differential value (y value) in the waveform (first curve) related to the coagulation rate is greater than the prescribed operation target region value. In more detail, the operation target region is a region (portion) in which the first differential value (y value) in the waveform related to the coagulation rate is greater than the prescribed operation target region value and less than the maximum value (Vmax), and includes the maximum point of the waveform. The operation target region value is a prescribed value that specifies the lower limit of the operation target region, and is also referred to as the operation target region value S in this specification. The operation target region value S can be set to a range for limiting the peak shape reflecting the waveform related to the coagulation rate. In order to relatively widely limit the peak shape, the operation target region value S can be set to 0% to 20% of Vmax. On the other hand, if the operation target region value S is increased, the influence of the upper shape of the peak is relatively greatly reflected in the analysis result. In order to analyze the shape of the upper part of the peak, the operation target region value S can be set to 20% to 95% of Vmax. In one embodiment, the calculation target region value S may be set to 0.5 to 99%, preferably 5 to 90%, of Vmax.

[0152] In the method of the present invention, multiple operation target areas are extracted based on multiple different operation target area values ​​S. The number of operation target areas extracted in the method of the present invention is not necessarily limited. When the number is small, the accuracy of the determination of the blood sample is sometimes reduced. On the other hand, if the number is too large, the amount of calculation increases and the calculation load becomes high. The multiple operation target areas are preferably 3 or more different areas, more preferably 5 or more different areas, more preferably 3 to 100 different areas, and more preferably 5 to 20 different areas. The number of operation target area values ​​S corresponds to the number of operation target areas. The operation target area values ​​S used to extract each operation target area are different from each other. From the perspective of analysis accuracy, it is preferred that each S is not close. The interval between each S can be set according to the number of operation target areas, preferably 1 / 100 to 1 / 2 of Vmax, more preferably 1 / 33 to 1 / 5 of Vmax, more preferably 1 / 20 to 1 / 5 of Vmax, and more preferably 1 / 20 to 1 / 10 of Vmax. The interval between Vmax and each S can be the same or different. The operation target area value S can also be applied to a quadratic curve. The quadratic curve may have peaks in both the positive and negative directions. The calculation target region value S may be set for the positive peak and the negative peak of the quadratic curve, respectively. In one embodiment, the calculation target region value S may be set to 0.5 to 99%, preferably 5 to 90%, of the maximum value of the positive peak of the quadratic curve. In another embodiment, the calculation target region value S may be set to 0.5 to 99%, preferably 5 to 90%, of the minimum value of the negative peak of the quadratic curve.

[0153] 1.3.3.3. Weighted average score

[0154] Reference Figure 8 The calculation target region and the weighted average score of the calculation target region will be described. Figure 8 The correction first-order curve F(t) (t=time) is shown in FIG. Figure 8 The maximum value Vmax of F(t) and the weighted average score (vTx, vHx) when the calculation target area value S of the parameter described below is x% of Vmax, and vB representing the peak width of the calculation target area are shown. The calculation target area is an area where the value of F(t) is greater than the calculation target area value S and less than the maximum value Vmax of the first differential value (F(t) ≥ S (S = x%)). The weighted average score (vTx, vHx) is equivalent to the "weighted average value" of the calculation target area of ​​F(t).

[0155] The coagulation reaction time (t) at the weighted average score is referred to as the weighted average time vT. That is, the weighted average time vT is the time from the coagulation reaction start time to the weighted average score, and is the x-coordinate of the weighted average score. The weighted average height vH is the y-coordinate of the weighted average score.

[0156] The weighted average time vT and weighted average height vH of the first order curve can be obtained by the following steps. First, the maximum value of the first order curve F(t) is Vmax, the value of the operation object area is S, and the data set of time t that satisfies F(t)≥Vmax×S×0.01 is set to t[t1,…t2](t1<t2). That is, F(t1)=Vmax×S×0.01, F(t2)=Vmax×S×0.01, and the data set of time t1 to t2 is t[t1,…t2](t1<t2). At this time, the product sum value M is obtained by the following formula (2).

[0157]

[0158] The weighted average time vT and the weighted average height vH are calculated by the following equations (3) and (4), respectively. The weighted average score (vTx, vHx) is derived from the obtained vT and vH.

[0159]

[0160]

[0161] In this specification, in order to identify vT and vH from different operation target areas, they are sometimes referred to as vTx and vHx respectively according to the operation target area value S (S=x%) from which they come. For example, vT and vH of the operation target area with S of 5% are vT5% and vH5%. These weighted average time vTx and weighted average height vHx can be used as parameters to characterize the operation target area. It should be noted that t1 and t2 (t1<t2) that satisfy the above-mentioned F(t1)=Vmax×S×0.01 and F(t2)=Vmax×S×0.01 can also be used as parameters. Hereinafter, t1 and t2 related to the first-order curve are sometimes referred to as the area start time vTs and the area end time vTe (vTs<vTe), respectively. These are sometimes also referred to as vTsx and vTex respectively according to the operation target area value S (S=x%).

[0162] Fig. 9 , the relationship between the calculation target region value S, the region (calculation target region) of the corrected zero-order curve and the corrected first-order curve as the analysis target at this time, and the weighted average score is shown. Fig. 9 The upper, middle, and lower sections show the cases where the calculation target region value S is 10%, 50%, and 80% of Vmax (=100%), respectively. The left side shows the calculation target region for the correction of the 0th order curve, and the right side shows the calculation target region for the correction of the 1st order curve. The black circle represents the weighted average score. As the calculation target region value S changes, the positions of the calculation target region and the weighted average score are shown in FIG. Fig. 9 In the above description, Figure 8 , Fig. 9As shown in FIG. 1 , the parameters related to the operation target region are calculated by correcting the primary curve, but the same parameters can be calculated even without correcting the primary curve.

[0163] Similarly, for quadratic curves, weighted average score, weighted average time and weighted average height can also be defined. Fig.10 As shown, there are peaks in both the positive and negative directions of the quadratic differential value. Therefore, the weighted average of the quadratic curve can be calculated for both the positive peak and the negative peak. For example, for the positive peak, when the maximum value of the quadratic curve A=F'(t) is Amax and the value of the calculation object area is S(%), the time t[t1,...,t2](t1<t2) that satisfies F'(t)≥Amax×S×0.01 is obtained, and the weighted average time pT and weighted average height pH of the positive peak are calculated according to the above formulas (2)' to (4)'. For the negative peak, when the minimum value of the quadratic curve A=F'(t) is Amin and the value of the calculation object area is S(%), the time t[t1,...,t2](t1<t2) that satisfies F'(t)≤Amin×S×0.01 is obtained, and the weighted average time mT and weighted average height mH of the negative peak are calculated according to the above formulas (2)', (3)' and (4)'. As the calculation target region value S changes, the position of the weighted average score changes.

[0164]

[0165]

[0166]

[0167]

[0168]

[0169] 1.3.3.4. Peak width, average score, flatness rate and time rate

[0170] The time length of the primary curve F(t) ≥ S (the value obtained by multiplying the data fraction of F(t) ≥ S by the photometry time interval) from the minimum reaction time in the area where the reaction time is shorter than the weighted average time vT and the maximum reaction time in the area where the reaction time is longer than the weighted average time vT and the first differential value is greater than the calculation object area value S) is taken as the peak width vB ​​of the primary curve. Figure 8In the example shown, the peak width is vB from time vTs to time vTe. Similarly, the second differential value of the positive peak of the secondary curve F'(t) is pTs and pTe, respectively, the minimum and maximum values ​​of the reaction time above the calculation target area value S, and the time length of F'(t) ≥ S from pTs to pTe (the value obtained by multiplying the data fraction of F'(t) ≥ S by the photometric time interval) is the peak width pB of the positive peak of the secondary curve. Similarly, the second differential value of the negative peak of the secondary curve F'(t) is mTs and mTe, respectively, the minimum and maximum values ​​of the reaction time below the calculation target area value S, and the time length of F'(t) ≤ S from mTs to mTe (the value obtained by multiplying the data fraction of F'(t) ≤ S by the photometric time interval) is the peak width mB of the negative peak of the secondary curve.

[0171] As a further example of the parameter used in the present invention, the regional time width vTr can be cited. vTr is the width (time length) from vTs to vTe. When the operation target region of the primary curve is a single peak, vTr=vB, but when the primary curve is a multi-peak containing a valley F(t)<S, vTr>vB. As a further example of the parameter used in the present invention, the main peak starting time vNs, the main peak end time vNe, and the main peak width vN can be cited. vNs and vNe are parameters of the main peak containing the maximum value Vmax in the operation target region of the primary curve, and are parameters that are less susceptible to the influence of noise that may be contained in the coagulation reaction curve than the above-mentioned vTs, vTe, etc. vNs is the largest time among the times that are less than the time (VmaxT described later) showing the maximum value Vmax and showing F(t)=S in the operation target region of the primary curve F(t). vNe is the smallest time among the times that are greater than VmaxT and showing F(t)=S in the operation target region of the primary curve F(t). When the operation target area is a single peak, vNs and vNe are the same values ​​as vTs and vTe. vN is the width (time length) from vNs to vNe. Similarly, pNs, pNe, pN and mNs, mNe, mN can be defined similarly for the positive and negative peaks of the quadratic curve F'(t). Fig.11 vTs, vTe, vTr, vNs, vNe, and vN are shown.

[0172] As a further example of the parameter used in the present invention, the weighted average peak width vW can be mentioned. Fig.12 The calculation target region (dashed line) of the linear curve when the calculation target region value S is 10% is shown. Fig.12 The upper figure in shows the weighted average score (vT, vH) (black circle), vTs, vTe, Fig.12 The following figure shows vB and vW. Fig.12As shown, vW is the peak width satisfying the first order curve F(t)≥vH (the time length of F(t)≥vH from the minimum time to the maximum time satisfying F(t)≥vH). The same parameters can be calculated using the uncorrected first order curve. Similarly, for the positive peak of the second order curve, the peak width satisfying F'(t)≥pH is taken as the weighted average peak width pW. For the negative peak of the second order curve, the width of the coagulation reaction time satisfying F'(t)≤mH is taken as the weighted average peak width mW.

[0173] Further examples of the parameters used in the present invention include average time vTa, average height vHa, and area center time vTm. Fig.13 The figure shows the average score (vTa, vHa) (white diamond mark), weighted average score (vT, vH) (black circle), vTs, vTe and vTm of the first-order curve when the calculation target area value S is 10%. When the data score from F(vTs) to F(vTe) is set to n, vTa, vHa and vTm are expressed by the following formulas.

[0174]

[0175]

[0176]

[0177] Similarly, the quadratic curve can also be determined by referring to equation (7) to obtain pTm, which is the midpoint between pTs and pTe, and mTm, which is the midpoint between mTs and mTe.

[0178] As parameters of the first-order curve used in the present invention, the weighted average height vH, the average height vHa, the peak width vB ​​and the weighted average peak width vW are used, and the flatness vAB, vABa based on the peak width and the flatness vAW, vAWa based on the weighted average peak width are defined as shown in the following formulas (8a), (8b), (8c) and (8d).

[0179] vAB=vH / vB (8a)

[0180] vAW=vH / vW (8b)

[0181] vABa=vHa / vB (8c)

[0182] vAWa=vHa / vW (8d)

[0183] In addition, using the weighted average time vT, peak width vB ​​and weighted average peak width vW as parameters of the linear curve, the time rate vTB based on the peak width and the time rate vTW based on the weighted average peak width are defined as shown in the following equations (9a) and (9b).

[0184] vTB=vT / vB (9a)

[0185] vTW=vT / vW (9b)

[0186] It should be noted that the flattening rate can be vAB=vB / vH, vAW=vW / vH, and can also be vABa=vB / vHa, vAWa=vW / vHa. That is, the flattening rate can be the ratio of the weighted average height vT or the average height vHa to the peak width vB ​​or vW. Similarly, the time rate can be vTB=vB / vT, vTW=vW / vT. That is, the time rate can be the ratio of the weighted average time vT to the peak width vB ​​or vW. In addition, these ratios can be multiplied by a constant K. That is, for example, the flatness rate can be vAB=(vH / vB)K, vAB=(vB / vH)K, vAW=(vH / vW)K or vAW=(vW / vH)K, or it can also be vABa=(vHa / vB)K, vABa=(vB / vHa)K, vAWa=(vHa / vW)K or vAWa=(vW / vHa)K, and the time rate can be vTB=(vT / vB)K, vTB=(vB / vT)K, vTW=(vT / vW)K or vTW=(vW / vT)K.

[0187] In addition, the flattening rate and time rate as described above can also be obtained for the quadratic curve. For example, for the positive peak of the quadratic curve, as the ratio of pH to pB or pW, the flattening rate pAB based on the peak width or the flattening rate pAW based on the weighted average peak width can be obtained. On the other hand, as the ratio of pT to pB or pW, the time rate pTB based on the peak width or the time rate pTW based on the weighted average peak width can be obtained. Similarly, for the negative peak of the quadratic curve, as the ratio of mH to mB or mW, the flattening rate mAB based on the peak width or the flattening rate mAW based on the weighted average peak width can be obtained. On the other hand, as the ratio of mT to mB or mW, the time rate mTB based on the peak width or the time rate mTW based on the weighted average peak width can be obtained.

[0188] The peak width vB, pB, mB, weighted average peak width vW, pW, mW, average time vTa, average height vHa, area start time vTs, pTs, mTs, area end time vTe, pTe, mTe, area center time vTm, pTm, mTm, area time width vTr, main peak start time vNs, pNs, mNs, main peak end time vNe, pNe, mNe, main peak width vN, pN, mN, flattening rate vAB, vAW, vABa, vAWa, pAB, pAW, mAB, mAW and time rate vTB, vTW, pTW, pAW, mTB, mTW as described above can also be parameters of the operation object area characterizing the primary curve.

[0189] In this specification, in order to identify parameters from different operation target areas, each parameter is sometimes displayed with annotated with the operation target area value S from which it comes. For example, the parameters of the operation target area representing the linear curve when S is x (%) are sometimes referred to as vHx, vTx, vBx, vWx, etc. For example, the parameters vH, vT, vB, vW, vTa, vHa, vTs, vTe, vTm, vTr, vNs, vNe, vN, vAB, vAW, vABa, vAWa, vTB, and vTW related to the weighted average score of the first order curve when S is 10% may be referred to as vH10%, vT10%, vB10%, vW10%, vTa10%, vHa10%, vTs10%, vTe10%, vTm10%, vTr10%, vNs10%, vNe10%, vN10%, vAB10%, vAW10%, vABa10%, vAWa10%, vTB10%, and vTW10%, respectively. The same applies to the parameters representing the operation target region of the second order curve.

[0190] Fig.14 A and Fig.14 B in denoted by represents a parameter when the operation target region value S is different for the same linear curve. Fig.14 A in the figure indicates that the calculation target area value S is 10%. Fig.14 B in the figure indicates that the calculation target area value S is 80%. Fig.14 In the case of A in FIG. 1 , the weighted average height vH10% of the first order curve is 0.4, the weighted average time vT10% is 149 seconds, and the peak width vB10% is 200 seconds. In contrast, in the case of 80% of the calculation target area value S, the weighted average height vH10% of the first order curve is 0.4, the weighted average time vT10% is 149 seconds, and the peak width vB10% is 200 seconds. Fig.14 In the case of B, the weighted average height vH80% is 0.72, the weighted average time vT80% is 119 seconds, and the peak width vB80% is 78 seconds.

[0191] 1.3.3.5. Others

[0192] As a further example of the parameter characterizing the operation target region used in the present invention, the area under the curve (AUC) of the operation target region of the first order curve or the second order curve can be cited. Since the second order curve has positive peaks and negative peaks, the area under the curve (AUC) of the operation target region may be the AUC (pAUC) of the operation target region with positive peaks and the AUC (mAUC) of the operation target region with negative peaks. In this specification, in order to identify the AUC from different operation target regions, it is sometimes referred to as AUCx according to the value S of the operation target region from which it comes. For example, the vAUC, pAUC and mAUC of the operation target region with S of 5% are vAUC5%, pAUC5% and mAUC5% respectively.

[0193] In addition, further parameters other than the above parameters characterizing the operation target area may be included in the parameters for determining the activity level or activity abnormality of the coagulation factor of the present invention. Examples of such parameters include the maximum first differential value Vmax, the maximum second differential value Amax, the minimum second differential value Amin, and VmaxT, AmaxT, AminT, etc. indicating the time to reach them.

[0194] The above series of parameters may include parameters from the coagulation reaction curve after correction processing (corrected 0th to 2nd order curves) and parameters from the coagulation reaction curve without correction processing (uncorrected 0th to 2nd order curves).

[0195] In the above, the parameters characterizing the waveform related to the coagulation rate or coagulation acceleration are described based on the coagulation reaction curve based on the scattered light amount. On the other hand, it is obvious to those skilled in the art that the same parameters can be obtained from the coagulation reaction curve based on other coagulation measurement methods (such as the transmitted light amount, absorbance). For example, the first-order curve F(t) obtained from the inverted S-shaped coagulation reaction curve based on the transmitted light amount is opposite in sign to the coagulation reaction curve based on the scattered light amount. In such a case, it is obvious to those skilled in the art that the sign of F(t) is reversed in the calculation of the parameters, for example, the maximum value Vmax is replaced by the minimum value Vmin, the operation object area is the area that satisfies F(t)≤S, vB and vW are the time lengths of F(t)≤x and F(t)≤vH from t1 to t2, respectively.

[0196] 1.4. Determination of specimens

[0197] An example of the determination performed in step 4 will be described.

[0198] 1.4.1. Creation of parameter groups

[0199] As described above, the parameters characterizing the operation target region of the waveform related to the coagulation rate or coagulation acceleration are extracted respectively. As the parameters characterizing the operation target region, the parameters related to the weighted average of the first order curve shown in Table A described later can be cited (weighted average time vT, weighted average height vH, average time vTa, average height vHa, peak width vB, weighted average peak width vW, flattening rates vAB, vAW, vABa, vAWa and time rates vTB, vTW obtained therefrom, and vAUC, vTs, vTe, vTr, vTm, vNs, vNe, vN) , parameters related to the weighted average of the quadratic curve (weighted average time pT, mT, weighted average height pH, mH, peak width pB, mB, weighted average peak width pW, mW, flattening rates pAB, pAW, mAB, mAW and time rates pTB, pTW, mTB, mTW obtained therefrom, and pAUC, mAUC, pNs, pNe, pN, mNs, mNe, mN, pTs, pTe, pTm, mTs, mTe, mTm). In the present invention, any one or more of these parameters may be extracted, or a parameter set containing two or more of them may be extracted. For example, the parameter may be at least one selected from vT, vH, vB, vAB and vTB, or a parameter set containing two or more of them. In a preferred embodiment, the parameter is a parameter set containing vT, vH, vB, vAB and vTB. In another preferred embodiment, the parameter is a parameter set including vB, vAB and vTB. In another preferred embodiment, the parameter is a parameter set including vB and vAB. In another preferred embodiment, the parameter is pH, pAB or vH. In another preferred embodiment, the parameter is a parameter set of pAB and pNe, a parameter set of pTW and vT, a parameter set of pTB and vABa, a parameter set of pAB and vNs or a parameter set of pTW, vTs and vW. The composition of the parameters characterizing each operation object area used in the method of the present invention is not limited to these embodiments.

[0200] Preferably, the multiple parameters (parameter group) used to determine the specimen in the method of the present invention include multiple parameters that respectively characterize multiple operation object areas of one waveform. In other words, the parameter group is a collection of multiple parameters extracted from multiple operation object areas of one waveform. Preferably, the parameter group includes one or more sets of the same parameters extracted from different operation object areas of one waveform (primary curve or secondary curve). For example, when L operation object areas are extracted and the parameter used is vHx, the parameter group consists of L vHx. For example, when 10 operation target areas based on 10 operation target area values ​​S (5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, and 90%) are extracted and the parameter vHx is extracted from each operation target area, the parameter group is a set of 10 vHx [vH5%, vH10%, vH20%, vH30%, vH40%, vH50%, vH60%, vH70%, vH80%, vH90%. Also, for example, when 5 operation target areas based on 5 operation target area values ​​S (5%, 20%, 40%, 60%, and 80%) are extracted and the parameter vHx is extracted from each operation target area, the parameter group is a set of 5 vHx [vH5%, vH20%, vH40%, vH60%, vH80%. Similarly, when M operation target areas are extracted and the parameters used are vBx, vABx and vTBx, the parameter group consists of M sets of [vBx, vABx, vTBx]. Alternatively, when N operation target areas are extracted and the parameters used are vTx, vHx, vBx, vABx and vTBx, the parameter group consists of N sets of [vTx, vHx, vBx, vABx, vTBx].

[0201] In addition, a plurality of parameters representing the operation target area may be combined with other parameters. For example, at least one selected from the maximum first differential value Vmax, the maximum second differential value Amax, the minimum second differential value Amin, and VmaxT, AmaxT, and AminT indicating the time to reach them shown in Table A described later may be combined with the plurality of parameters representing the operation target area described above.

[0202] 1.4.2. Target clotting time prolonging factor components

[0203] As the target blood coagulation time extension factor component that uses the method of the present invention to determine the activity level or abnormal activity, any endogenous or exogenous component that participates in the coagulation reaction that causes blood coagulation time extension can be cited. Preferably, the target blood coagulation time extension factor component is a coagulation factor. The coagulation factor is preferably at least one selected from the coagulation factors comprising FVIII and FIX, more preferably at least FVIII. FVIII and FIX can also be used as targets together.

[0204] 1.4.3. Template specimen

[0205] In the method of the present invention, a parameter group (hereinafter referred to as a test parameter group) including multiple parameters respectively extracted from multiple operation object areas of the waveform related to the coagulation rate or coagulation acceleration of the above-mentioned test specimen is compared with a parameter group (hereinafter referred to as a template parameter group) corresponding to a template blood specimen (hereinafter also referred to as a template specimen). Based on the result of the comparison, the coagulation characteristics of the test specimen, preferably the activity level or activity abnormality of the coagulation time prolonging factor component in the test specimen, are determined. In the present invention, it is preferred to prepare more than one template specimen. The template specimen is a blood specimen for which the activity level of the target coagulation time prolonging factor component in the method of the present invention or the presence or absence of activity abnormality is known.

[0206] For example, when evaluating FVIII, the one or more template samples include one or more blood samples with normal FVIII activity levels (FVIII normal samples) and one or more blood samples with abnormal FVIII activity levels (FVIII abnormal samples, such as FVIII deficiency samples). For example, when evaluating FIX, the one or more template samples include one or more blood samples with normal FIX activity levels (FIX normal samples) and one or more blood samples with abnormal FIX activity levels (FIX abnormal samples, such as FIX deficiency samples). For example, when evaluating FVIII and FIX, the one or more template samples include one or more blood samples in which the activity levels of FVIII and FIX are not abnormal (FVIII / FIX normal samples), one or more blood samples in which the activity level of FVIII is abnormal (FVIII abnormal samples, such as FVIII deficiency samples), and one or more blood samples in which the activity level of FIX is abnormal (FIX abnormal samples, such as FIX deficiency samples).

[0207] Preferably, the FVIII abnormal specimen includes blood specimens from severe, moderate and mild hemophilia A patients. Preferably, the blood specimens from severe, moderate and mild hemophilia A patients are blood specimens with FVIII activity less than 1%, more than 1% and less than 5%, and more than 5% and less than 40% (the value when the activity of a normal person is set to 100%, the same below), respectively. When a more detailed analysis is required, multiple specimens from severe hemophilia A patients with different FVIII activity levels can be prepared as needed. For example, specimens from patients with moderately severe hemophilia A (MS-HA) with a FVIII activity of more than 0.2% and less than 1% and specimens from patients with very severe hemophilia A (VS-HA) with a FVIII activity of less than 0.2% can be prepared. In recent years, it has been reported that among patients with severe hemophilia A, there is a difference in clinical severity, especially between patients with VS-HA who have low FVIII activity (FVIII activity less than 0.2%) and patients with MS-HA who do not (FVIII activity is 0.2% or more and less than 1%) (Tomoko Matsumoto, Jun Shima, Application of Coagulation Waveform Analysis and Micro-Assay of Factor VIII, 2003, Vol. 14, No. 2, p. 122-127). Identifying patients with VS-HA is useful for providing appropriate treatment to patients.

[0208] Similarly, the FIX abnormality specimen preferably includes blood specimens from severe, moderate and mild hemophilia B patients. Preferably, the specimens from the severe, moderate and mild hemophilia B patients have FIX activity less than 1%, more than 1% and less than 5%, and more than 5% and less than 40% (the value when the activity of a normal person is set to 100%, the same below). When implementing a more detailed analysis, multiple specimens from severe hemophilia B patients with different FIX activity levels can be prepared as needed. For example, a specimen with a FIX activity of more than 0.2% and less than 1% and a specimen with a FIX activity of less than 0.2% can be prepared.

[0209] Regression analysis

[0210] In the method of the present invention, regression analysis of corresponding parameters is performed between the parameter group to be tested and each template parameter group from each template specimen.

[0211] The template parameter group used in the regression analysis is obtained by performing the data analysis described in 1.3. above on each template specimen. In this data analysis, the number of extracted operation object areas and a series of operation object area values ​​S used in the extraction of multiple operation object areas are set to the same values ​​as those in the data analysis of the specimen to be tested. In addition, the types of parameters contained in the template parameter group are the same as those in the parameter group to be tested. For example, if the parameter group to be tested is L vHx, then the template parameter group of the template specimen is also L vHx. In addition, for example, if the parameter group to be tested is M sets of [vBx, vABx, vTBx], then the template parameter group of the template specimen is also M sets of [vBx, vABx, vTBx]. In addition, for example, if the parameter group to be tested is N sets of [vTx, vHx, vBx, vABx, vTBx], then the template parameter group of the template specimen is also N sets of [vTx, vHx, vBx, vABx, vTBx]. Therefore, the template parameter group is a parameter group of the template specimen corresponding to the inspected parameter group. That is, each parameter contained in each template parameter group corresponds to each parameter contained in the inspected parameter group. It should be noted that in this specification, when the parameters of the template parameter group correspond to the parameters of the inspected parameter group, the parameters of the template parameter group and the parameters of the inspected parameter group are the same type of parameters. For example, vTx, vHx, vBx, vABx and vTBx of the inspected parameter group correspond to vTx, vHx, vBx, vABx and vTBx (x is a specified value) of the template parameter group, respectively. A template parameter group composed of parameters corresponding to all the parameters of the inspected parameter group corresponds to the inspected parameter group.

[0212] The template parameter set is preferably obtained in advance. In addition, each template parameter set may also be a synthetic parameter set obtained by processing parameter sets obtained from multiple template specimens. For example, parameter sets may be obtained for multiple template specimens with the same activity level of the target clotting time prolonging factor component and statistically processed to produce one or more synthetic parameter sets representing the standard template specimen.

[0213] The method of regression analysis is not particularly limited, and for example, linear regression based on the least squares method can be cited. For example, the value of each parameter in the test parameter group is plotted as the y-axis, and the value of the corresponding parameter in any one of the template parameter groups is plotted as the x-axis to obtain a regression line. The correlation between the test parameter group and each template parameter group is investigated based on the slope, intercept, correlation (correlation coefficient, determination coefficient, etc.) of the regression line. The correlation between the test parameter group and the template parameter group reflects the correlation (approximate state) of the coagulation characteristics between the test specimen and the template specimen from which the template parameter group comes.

[0214] 1.4.5. Determination of coagulation characteristics

[0215] Next, based on the results of the regression analysis, the coagulation characteristics of the sample to be tested are determined. Preferably, the determination of the coagulation characteristics is the determination of the activity level of the target clotting time extension factor component or the abnormal activity thereof. Below, the determination steps are described by taking the case where the target clotting time extension factor component is FVIII as an example. For other factors such as FIX, it is also possible to determine them according to the same steps.

[0216] The FVIII activity level and activity abnormality (deficiency, etc.) of the test sample are determined based on the correlation between the test sample and one or more template samples obtained in the above regression analysis. Preferably, the correlation is the correlation of the regression line (e.g., slope, intercept, correlation coefficient, determination coefficient, etc.).

[0217] An embodiment of determining the FVIII activity level or abnormal activity of the sample to be tested based on the correlation is described below. The template sample includes one or more FVIII normal samples and one or more FVIII abnormal samples with different FVIII activity levels. Preferably, the template sample includes one or more FVIII normal samples and one or more FVIII abnormal samples from patients with severe (VS-HA and MS-HA as needed), moderate and mild hemophilia A. At least one sample whose correlation between the tested parameter group and the template parameter group meets the specified conditions is selected from all template samples used for regression analysis.

[0218] In one embodiment, a template sample is selected for which the correlation is above a preset threshold. In another embodiment, a template sample is selected for which the correlation is above a preset threshold and the correlation is the highest. In another embodiment, a template sample is selected for which the slope of the regression line between the tested parameter group and the template parameter group is within a prescribed range (e.g., 0.70 to 1.30, preferably 0.75 to 1.25, more preferably 0.80 to 1.20, further preferably 0.85 to 1.15, further preferably 0.87 to 1.13). In another embodiment, a template sample is selected for which the slope of the regression line between the tested parameter group and the template parameter group is within the above prescribed range and the correlation coefficient of the regression line is above a prescribed value (e.g., greater than 0.75, preferably greater than 0.80, more preferably greater than 0.85, further preferably greater than 0.90). On the other hand, when a template sample that satisfies the prescribed condition cannot be selected, the prescribed condition can be changed and the template sample can be selected again, or it can be evaluated as "no template sample selected".

[0219] In a preferred embodiment, a template specimen whose slope of the regression line is within a specified range (e.g., 0.70 to 1.30, preferably 0.75 to 1.25, more preferably 0.80 to 1.20, further preferably 0.85 to 1.15, further preferably 0.87 to 1.13) is selected. It is preferred to select a template specimen whose slope of the regression line is within the above-mentioned specified range and whose correlation coefficient of the regression line is greater than a specified value (e.g., greater than 0.75, preferably greater than 0.80, more preferably greater than 0.85, further preferably greater than 0.90). From the selected template specimens, the template specimen with the highest correlation coefficient of the regression is selected. When multiple template specimens that meet the specified conditions are selected, one template specimen can be selected from them based on further criteria.

[0220] Next, the state of FVIII of the selected template specimen (i.e., the activity level or abnormal activity of FVIII) is determined as the state of FVIII of the test specimen. When multiple template specimens are selected, it can be determined that the state of FVIII of the test specimen is equivalent to any one of the states of the multiple template specimens, or the average state of the multiple template specimens can be determined as the state of FVIII of the test specimen.

[0221] For example, if the selected template specimen is a normal FVIII specimen, the state of FVIII of the specimen to be tested can be determined to be normal. On the other hand, if the selected template specimen is an abnormal FVIII specimen, the specimen to be tested can be determined to have an abnormality in FVIII activity. In addition, for example, if the selected template specimen is a specimen from a patient with severe, moderate, and mild hemophilia A, the specimen to be tested can be determined to be severe, moderate, and mild hemophilia A, respectively. In addition, when the template specimen contains specimens from a patient with severe hemophilia A from VS-HA and MS-HA, if a template specimen from a VS-HA or MS-HA patient is selected, the specimen to be tested can be determined to be VS-HA or MS-HA. Alternatively, when determining the FVIII activity level of the specimen to be tested, the FVIII activity level of the selected template specimen can be determined as the FVIII activity level of the specimen to be tested.

[0222] On the other hand, if the template sample includes samples from severe, moderate and mild hemophilia A patients and the above correlation evaluation shows "no template sample selected", then the sample to be tested can be judged as "not having abnormal FVIII activity" or the "main factor for prolonged clotting time of the sample to be tested is not caused by abnormal FVIII activity".

[0223] In another preferred embodiment, the template specimens whose slopes of all the regression lines are within a specified range (e.g., 0.70 to 1.30, preferably 0.75 to 1.25, more preferably 0.80 to 1.20, further preferably 0.85 to 1.15, further preferably 0.87 to 1.13) are selected. It is preferred to select template specimens whose slopes of all the regression lines are within the above-mentioned specified range and whose correlation coefficients of the regression lines are above a specified value (e.g., greater than 0.75, preferably greater than 0.80, more preferably greater than 0.85, further preferably greater than 0.90). The state of FVIII (i.e., the activity level or activity abnormality of FVIII) found with the highest frequency among the selected template specimens is determined as the state of FVIII in the specimen to be tested.

[0224] For example, if the number of normal FVIII specimens in the selected template specimen is the largest, the state of FVIII in the specimen to be tested can be determined to be non-abnormal. On the other hand, if the number of abnormal FVIII specimens in the selected template specimen is the largest, the specimen to be tested can be determined to be abnormal with FVIII activity. In addition, for example, when the number of specimens from severe, moderate and mild hemophilia A patients in the selected template specimen is the largest, the specimen to be tested can be determined as severe, moderate and mild hemophilia A, respectively. In addition, for example, when the number of specimens from severe hemophilia A patients from VS-HA and MS-HA in the selected template specimen is the largest, the specimen to be tested can be determined as VS-HA and MS-HA, respectively. In addition, for example, when the number of non-abnormal FVIII prolongation of coagulation time specimens in the selected template specimen is the largest, the specimen to be tested can be determined as an abnormal specimen other than hemophilia A patients (severe, moderate and mild). Alternatively, when determining the FVIII activity level of the test sample, the FVIII activity level found at the highest frequency in the selected template sample can be determined as the FVIII activity level of the test sample.

[0225] In another preferred embodiment, all template specimens whose slopes of the regression lines are within a specified range (e.g., 0.70 to 1.30, preferably 0.75 to 1.25, more preferably 0.80 to 1.20, further preferably 0.85 to 1.15, further preferably 0.87 to 1.13) are selected. It is preferred to select template specimens whose slopes of the regression lines are within the above-mentioned specified range and whose correlation coefficients of the regression lines are above a specified value (e.g., greater than 0.75, preferably greater than 0.80, more preferably greater than 0.85, further preferably greater than 0.90).

[0226] The selected template specimen is divided into specimens from hemophilia A patients (severe, moderate and mild) with low FVIII activity and specimens other than this according to the FVIII activity level. When the number of the former is more than the number of the latter, the severity (any one of severe, moderate and mild) most visible in the specimen of the former is determined as the state of the specimen to be tested. When there are specimens with the same number of different severity, the more severe state can be determined as the state of the specimen to be tested, or the specified conditions can be changed and the template specimen can be selected again. On the other hand, when the number of the latter is more than the number of the former, the specimen to be tested is determined to be a specimen other than hemophilia A patients (severe, moderate and mild).

[0227] As described above, the FVIII activity level of the test specimen or the presence or absence of activity abnormality can be determined by the method of the present invention. In another embodiment, it is determined whether there is abnormal activity of FVIII in the test specimen, and the determination provides information on whether the test specimen is a specimen of a hemophilia A patient. In another embodiment, the FVIII activity level of the test specimen is determined, and the determination provides information on the determination of the severity of hemophilia A of the patient who provided the test specimen. Therefore, one embodiment of the analysis method of the blood specimen of the present invention can be a method for determining hemophilia A, for the severity of hemophilia A, such as severe (VS-HA and MS-HA as needed), moderate and mild.

[0228] In one embodiment, in addition to the above-mentioned determination about FVIII, the test specimen can also be determined about other clotting time extension factor components. Preferably, the other clotting time extension factor components are FIX. For example, the test specimen determined as "the extension factor of clotting time is not caused by abnormal FVIII activity" or "except hemophilia A patients (severe, moderate and mild)" in the above-mentioned determination about FVIII can be determined to determine the activity level of FIX or its abnormal activity. The determination step of the activity level of FIX or its abnormal activity can be implemented according to the same steps as the above-mentioned determination step about FVIII. The template specimen used in the determination about FIX can be the same or different from the template specimen used in the evaluation about FVIII. In addition, the tested parameter group and template parameter group used in the determination about FIX can be the same or different from the tested parameter group and template parameter group used in the determination about FVIII. In one example of the present embodiment, it is determined whether there is abnormal activity of FIX in the test specimen, and the determination provides information on whether the test specimen is a specimen of a hemophilia B patient. In another example of the present embodiment, the FIX activity level of the test specimen is determined, and the determination provides information on the determination of the severity of hemophilia B of the patient who provided the test specimen. The present embodiment can determine hemophilia B and the severity of hemophilia B (e.g., severe, moderate and mild). In addition, by combining the above-mentioned evaluation of FVIII with the evaluation of FIX, the coagulation characteristics of the test specimen can be analyzed more comprehensively.

[0229] 2. Program and apparatus for the method of the present invention

[0230] The above-mentioned blood sample analysis method of the present invention can be automatically performed using a computer program. Therefore, one embodiment of the present invention is a program for performing the above-mentioned blood sample analysis method of the present invention. In addition, a series of steps of the above-mentioned method of the present invention, including the preparation of the sample of the test sample and the determination of the coagulation time, can be automatically performed using an automatic analysis device. Therefore, one embodiment of the present invention is a device for performing the above-mentioned blood sample analysis method of the present invention.

[0231] Hereinafter, one embodiment of the device of the present invention will be described. One embodiment of the device of the present invention is as follows Fig.15 The automatic analyzer 1 is shown. The automatic analyzer 1 includes a control unit 10 , an operation unit 20 , a measurement unit 30 , and an output unit 40 .

[0232] The control unit 10 controls the overall operation of the automatic analyzer 1. The control unit 10 can be composed of a personal computer (PC), for example. The control unit 10 has a CPU, a memory, a storage, a communication interface (I / F), etc., and performs processing of instructions from the operation unit 20, control of the operation of the measuring unit 30, storage of the measurement data received from the measuring unit 30, data analysis, storage of the analysis results, and control of the output of the measurement data and the analysis results based on the output unit 40. In addition, the control unit 10 can also be connected to other devices such as external media and a host. It should be noted that in the control unit 10, the PC that controls the operation of the measuring unit 30 and the PC that performs the analysis of the measurement data can be the same or different.

[0233] The operation unit 20 obtains input from the operator and sends the obtained input information to the control unit 10. For example, the operation unit 20 includes a user interface (UI) such as a keyboard and a touch panel. The output unit 40 outputs the measurement data of the measurement unit 30 and the analysis results of the data under the control of the control unit 10. For example, the output unit 40 includes a display device such as a display.

[0234] The measuring unit 30 performs a series of operations for the coagulation test and obtains the measurement data of the coagulation reaction of the sample containing the blood sample. The measuring unit 30 is equipped with various equipment and analysis modules required for the coagulation test, such as a sample container for storing the blood sample, a reagent container for storing the test reagent, a reaction container for the reaction between the sample and the reagent, a probe for injecting the blood sample and the reagent into the reaction container, a light source, a detector for detecting scattered light or transmitted light from the sample in the reaction container, a data processing circuit for sending data from the detector to the control unit 10, and a control circuit for receiving instructions from the control unit 10 to control the operation of the measuring unit 30.

[0235] The control unit 10 analyzes the coagulation characteristics of the specimen based on the data measured by the measuring unit 30. This analysis may include the acquisition of the above-mentioned coagulation reaction curve, waveforms related to the coagulation rate and coagulation acceleration, extraction of parameter groups of the specimen to be tested, extraction of template parameter groups of the template specimen, regression analysis of these parameter groups, and determination of the activity level or activity abnormality of the target coagulation time prolonging factor component of the specimen to be tested based on the results of the regression analysis. This analysis can be implemented by a program for performing the method of the present invention. Therefore, the control unit 10 may be equipped with a program for performing the method of the present invention.

[0236] In the analysis using the control unit 10 described above, the coagulation reaction curve and the waveform related to the coagulation rate and the coagulation acceleration used in the analysis can be produced by the control unit 10 based on the measurement data from the measuring unit 30, or can be produced by another device, such as the measuring unit 30 and sent to the control unit 10. Alternatively, the coagulation reaction curve can be produced by the measuring unit 30 and sent to the control unit 10, and the waveform related to the coagulation rate or the coagulation acceleration can be produced by the control unit 10. The data of the template parameter group of the template specimen can be produced by measuring the template specimen in advance by the measuring unit 30 and analyzing the obtained measurement data by the control unit 10, or can be obtained from the outside. The data of the template parameter group can be stored in the memory of the control unit 10 or in an external device. The regression analysis method and the judgment criterion for analyzing the coagulation characteristics of the specimen to be tested based on the result of the regression analysis can be controlled by the program of the present invention.

[0237] The analysis result of the control unit 10 is sent to the output unit 40 for output. The output can be displayed on the screen, sent to the host, printed, etc. The output information from the output unit includes the determination result of the target coagulation time extension factor component of the test specimen (for example, the FVIII activity level, the determination result of hemophilia A or its severity, etc.), and can include the result of regression analysis of the test specimen and the template specimen (for example, regression linear equation, correlation), the coagulation reaction curve of the test specimen and the template specimen, and the waveform related to the coagulation speed or coagulation acceleration, etc. The type of output information from the output unit can be controlled by the program of the present invention.

[0238] In one embodiment, the automatic analyzer 1 may be configured as a general automatic analyzer for blood coagulation testing that is conventionally used for measuring coagulation time such as APTT and PT, in addition to being provided with a program for performing the method of the present invention.

[0239] Example

[0240] Hereinafter, the present invention will be described in detail using examples, but the present invention is not limited to the following examples.

[0241] The parameters used in the following embodiments, unless otherwise specified, represent parameters from the corrected zero-order curve to the corrected quadratic curve. On the other hand, the parameters from the uncorrected zero-order curve to the uncorrected quadratic curve are indicated by annotating R at the beginning of the name of each parameter. For example, when the weighted average height of the corrected first-order curve is vH, the weighted average height of the uncorrected first-order curve is represented by RvH, and when the weighted average height of the corrected second-order curve is pH, the weighted average height of the uncorrected second-order curve is represented by RpH. The parameters are listed in Table A below.

[0242] [Table A]

[0243] [Table A]

[0244] Waveform parameters of first order and second order curves

[0245]

[0246] x: value of the operation area k: constant

[0247] Parameters from uncorrected coagulation curves are preceded by R.

[0248] Example 1 Calculation of Test Parameters

[0249] (1) Methods

[0250] As a reagent for determination, COAGPIAAPTT-N (manufactured by Sekisui Medical Co., Ltd.), which is a reagent for APTT determination, is used, and as a calcium chloride solution, COAGPIAAPTT-N calcium chloride solution (manufactured by Sekisui Medical Co., Ltd.) is used. The coagulation reaction measurement of the sample containing the specimen is carried out using a coagulation automatic analyzer CP3000 (manufactured by Sekisui Medical Co., Ltd.). In a cuvette, 50 μL of a determination reagent at about 37°C is added to 50 μL of a specimen heated at 37°C for 45 seconds, and 50 μL of a 25 mM calcium chloride solution is further added after 171 seconds to start the coagulation reaction. The reaction is carried out at 37°C. In the determination of the coagulation reaction, the cuvette is irradiated with light of a wavelength of 660 nm using an LED as a light source, and the amount of scattered light of the 90-degree side scattered light is measured at intervals of 0.1 seconds. The measurement time is 360 seconds. The coagulation reaction curve is obtained from the obtained time-measured data.

[0251] (2) Blood samples to be tested

[0252] 34 samples (plasma) were analyzed. The 34 samples included 24 FVIII deficiency samples (13 severe (FVIII < 1%), 8 moderate (FVIII = 1-5%), and 3 mild (FVIII = 5-40%)) and 10 samples other than FVIII deficiency samples (Other). The coagulation reaction curve of each sample was obtained according to the procedure (1).

[0253] (3) Template specimen

[0254] The composition of the template specimens used in the analysis is shown in Table 1. 43 specimens with different FVIII activities and 88 specimens with normal FVIII activity but prolonged coagulation time due to other major factors were prepared. The FVIII activity of the former 43 specimens belonged to any of severe hemophilia A (FVIII <1%), moderate (FVIII = 1-5%), mild (FVIII = 5-40%) and other (FVIII > 40% is Other). Since the FVIII activity of the latter 88 specimens was not abnormal, they belonged to "Other" in the classification of Table 1. A total of 131 specimens were used as template specimens for analysis, and the coagulation reaction curve of each specimen was obtained according to the procedure (1).

[0255] [Table 1]

[0256] Composition of template specimen

[0257]

[0258] Specimens with other factors: Deficiency of coagulation factors other than FVIII, plasma with heparin, and LA-positive plasma

[0259] (4) Data analysis

[0260] (4-1) Calculation of the first-degree curve

[0261] A corrected first-order curve is calculated from the coagulation reaction curve of the specimen obtained in (2). First, the coagulation reaction curve is preprocessed. That is, the coagulation reaction curve is smoothed including noise removal, and the amount of scattered light at the start of measurement is adjusted to 0. Next, the coagulation reaction curve is corrected so that the maximum height is 100, and the obtained corrected coagulation reaction curve (corrected 0th-order curve) is differentiated once to calculate the corrected first-order curve.

[0262] (4-2) Preparation of the parameter group to be tested

[0263] (Parameter Group A)

[0264] 10 operation target areas are extracted from the obtained corrected primary curve. The operation target area value S is set to 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% and 90% respectively relative to the maximum height value Vmax (100%) of the corrected primary curve. The peak width vB ​​is calculated for the operation target area under each S, and the weighted average time vT and weighted average height vH are calculated using the above formulas (2), (3) and (4). From the obtained vT and vH, the flattening rate vAB and the time rate vTB are calculated by the following formulas.

[0265] vAB=(vH / vB)K 1 (K1 =100)

[0266] vTB=(vT / vB)K 2 (K 2 =1)

[0267] The above steps are used to calculate the parameters of 10 operation target areas (S = 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% and 90%): vB [vB5%, vB10%, vB20%, vB30%, vB40%, vB50%, vB60%, vB70%, vB80%, vB90%], vT [vT5%, vT10%, vT20%, vT30%, vT40%, vT50%, vT60%, vT70%, vT80%, vT90%], vH [vH5%, vH10%, vH20%, vH30%, vH40%, vB50%, vB60%, vB70%, vB80%, vB90%], and vH [vH5%, vH10%, vH20%, vH30%, vH40%, vB50%, vB60%, vB70%, vB80%, vB90%] 0%, vH20%, vH30%, vH40%, vH50%, vH60%, vH70%, vH80%, vH90%], vAB [vAB5%, vAB10%, vAB20%, vAB30%, vAB40%, vAB50%, vAB 60%, vAB70%, vAB80%, vAB90%], and vTB [vTB5%, vTB10%, vTB20%, vTB30%, vTB40%, vTB50%, vTB60%, vTB70%, vTB80%, vTB90%].

[0268] The calculated parameters of the test object are combined to create a test parameter group as follows:

[0269] (Parameter group A-1) a parameter group consisting of 50 parameters: vB [vB5%, vB10%, ..., vB90%], vT [vT5%, vT10%, ..., vT90%], vH [vH5%, vH10%, ..., vH90%], vAB [vAB5%, vAB10%, ..., vAB90%] and vTB [vTB5%, vTB10%, ..., vTB90%];

[0270] (Parameter group A-2) A parameter group consisting of 30 parameters: vB [vB5%, vB10%, ..., vB90%], vAB [vAB5%, vAB10%, ..., vAB90%], and vTB [vTB5%, vTB10%, ..., vTB90%];

[0271] (Parameter group A-3) A parameter group consisting of 20 parameters: vB [vB5%, vB10%, ..., vB90%] and vAB [vAB5%, vAB10%, ..., vAB90%].

[0272] For comparison, the maximum value (Vmax) of the curve obtained by first differentiating the corrected 0th order curve and the time until reaching it (VmaxT), and the maximum value (Amax) of the curve obtained by second differentiating it and the time until reaching it (AmaxT) are calculated. These are parameters based on the parameters used in the waveform analysis of the conventional coagulation reaction curve (see Patent Documents 1 and 2). In addition to these conventional parameters, a test parameter group is further prepared as follows:

[0273] (Parameter group A-4) A parameter group consisting of 54 parameters in which Vmax, Amax, VmaxT and AmaxT are added to parameter A-1;

[0274] (Comparison parameter group 1) A parameter group consisting of four parameters: Vmax, Amax, VmaxT, and AmaxT.

[0275] (Parameter Group B)

[0276] Furthermore, using vB, vT, vH, vAB, and vTB of five operation target areas (S=5%, 20%, 40%, 60%, and 80%), a test parameter group is created as follows:

[0277] (Parameter group B-1) A parameter group consisting of 25 parameters: vB [vB5%, vB20%, vB40%, vB60%, vB80%], vT [vT5%, vT20%, vT40%, vT60%, vT80%], vH [vH5%, vH20%, vH40%, vH60%, vH80%], vAB [vAB5%, vAB20%, vAB40%, vAB60%, vAB80%] and vTB [vTB5%, vTB20%, vTB40%, vTB60%, vTB80%];

[0278] (Parameter group B-2) A parameter group consisting of 15 parameters: vB [vB5%, vB20%, vB40%, vB60%, vB80%], [vAB5%, vAB20%, vAB40%, vAB60%, vAB80%], and vTB [vTB5%, vTB20%, vTB40%, vTB60%, vTB80%];

[0279] (Parameter group B-3) A parameter group consisting of 10 parameters: vB [vB5%, vB20%, vB40%, vB60%, vB80%] and vAB [vAB5%, vAB20%, vAB40%, vAB60%, vAB80%];

[0280] (Parameter group B-4) A parameter group consisting of 29 parameters in which Vmax, Amax, VmaxT, and AmaxT are added to parameter B-1.

[0281] (4-3) Analysis of template samples

[0282] From the coagulation reaction curves of each template specimen obtained in (3), a corrected primary curve is calculated according to steps (4-1) to (4-2), and then, template parameter groups A-1 to A-4, B-1 to B-4 and comparison template parameter group 1 are prepared, each having the composition of the above-mentioned parameter groups A-1 to A-4, B-1 to B-4 and comparison parameter group 1.

[0283] Table 2 shows the composition of the prepared parameter group.

[0284] [Table 2]

[0285] Composition of each parameter group used in the analysis

[0286]

[0287] Example 2 Determination of FVIII activity or abnormality of a test sample using a parameter group

[0288] (1) Determination of FVIII activity

[0289] A regression analysis is performed between the test parameter group obtained from the test sample and the corresponding template parameter group obtained from each template sample. The parameter group A-1 obtained in Example 1 is used as the parameter group. Fig.16 The top five results from the regression analysis of the correlation coefficients of the samples from patients with severe hemophilia A (VS-HA) with FVIII activity less than 0.2% (Sample AF, APTT: 118.1 seconds, FVIII < 0.2%) are shown in the figure. Fig.16 The labels of the horizontal and vertical axes of each figure represent the FVIII activity and APTT of the template specimen and the test specimen, respectively. Since the correlation coefficient of these 5 samples is above 0.98, it is confirmed that there are template specimens with high correlation with the parameter group between the test specimen Sample AF. In addition, it is confirmed that the 5 selected template specimens (Template A to Template E) are all specimens from VS-HA patients with FVIII activity less than 0.2%.

[0290] Fig.17 A in the figure shows Fig.16 The regression line of the sample (Template A) with the highest correlation coefficient. Fig.17B in the figure shows the calibrated primary curves of the sample (Sample AF) and Template A. The calibrated primary curves of the sample (Sample AF) and Template A have very similar shapes, indicating that the coagulation properties of the two samples are similar. These results make it clear that this analysis can be used to determine the FVIII activity of blood samples. In addition, it is clear that this analysis is also effective for the detection of VS-HA patient samples.

[0291] (2) Determination of the severity of hemophilia A

[0292] Regression analysis of 34 test specimens and each template specimen was performed for parameter groups A-1 to A-4, B-1 to B-4 and comparison parameter group 1 obtained in Example 1. The linear regression equation of the parameter group was obtained between the test specimen and all template specimens, and the template specimens with the slope of the regression line in the range of 0.87 to 1.13 were selected. Next, the template specimen with the highest correlation coefficient was selected from the selected template specimens as the template specimen with the highest correlation. The FVIII activity of the selected template specimen was determined as the FVIII activity of the test specimen. Based on the determination results, the FVIII activity level of the test specimen was classified into 4 levels (FVIII activity: <1%, 1-5%, 5-40% and Other). The FVIII activity level consistency rate and FVIII deficiency consistency rate in this determination were calculated using the following formula based on the FVIII activity level of the classified test specimen and the actual FVIII activity level of the test specimen obtained by the one-step coagulation method. The FVIII activity level agreement rate indicates the ratio of the FVIII activity level of the determined sample to the actual FVIII activity level of the sample, and the FVIII deficiency agreement rate indicates the ratio of the FVIII deficiency of the determined sample to the actual FVIII deficiency of the sample.

[0293] FVIII activity level consistency rate (%) = (A11 + A22 + A33 + A44) / D × 100

[0294] FVIII deficiency consistency rate (%) = (A11 + A12 + A13 + A21 + A22 + A23 + A31 + A32 + A33 + A44) / D × 100

[0295]

[0296] Tables 3 to 5 are comparison tables of the determined FVIII activity of the test specimens and the actual FVIII activity of the test specimens. The comparison when using parameter groups A-1 to A-4 is shown in Table 3, the comparison when using parameter groups B-1 to B-4 is shown in Table 4, and the comparison when using comparative parameter group 1 is shown in Table 5.

[0297] [Table 3]

[0298] [Table 3-A1] Analysis results using parameter group A-1

[0299]

[0300] [Table 3-A2] Analysis results using parameter group A-2

[0301]

[0302] [Table 3-A3] Analysis results using parameter group A-3

[0303]

[0304] [Table 3-A4] Analysis results using parameter group A-4

[0305]

[0306] [Table 4]

[0307] [Table 4-B1] Analysis results using parameter group B-1

[0308]

[0309] [Table 4-B2] Analysis results using parameter group B-2

[0310]

[0311] [Table 4-B3] Analysis results using parameter group B-3

[0312]

[0313] [Table 4-B4] Analysis results using parameter group B-4

[0314]

[0315] [Table 5]

[0316] [Table 5] Analysis results using parameter set 1

[0317]

[0318] The types of parameter groups used in the analysis, the FVIII deficiency consistency rate, and the FVIII activity level consistency rate are summarized in Table 6. In the method using parameter group A or B, the FVIII activity level of the test sample can be determined with a high consistency rate.

[0319] [Table 6]

[0320]

[0321] Example 3: Differences in judgment results due to differences in correlation evaluation criteria

[0322] In order to confirm the difference in the determination results due to the difference in the evaluation criteria of the correlation, a comparative study was carried out under the following two conditions, in which only the evaluation criteria of the correlation were different. The parameter group A-4 was used.

[0323] Correlation evaluation criterion 1: Calculate the linear regression equation of the parameter group between all template specimens and the specimens to be tested, select the template specimens whose slope of the regression line is in the range of 0.87 to 1.13, and select the template specimen with the highest correlation coefficient from the selected template specimens (the same evaluation criterion as Example 2).

[0324] Correlation evaluation criterion 2: Calculate the linear regression equation of the parameter group between all template samples and the samples to be tested, and select the template sample with the highest correlation coefficient.

[0325] The determination results are shown in Table 7 (Table 7-1 is the same as Table 3A-4). Table 8 summarizes the types of parameters used in the analysis, the FVIII deficiency consistency rate, and the FVIII activity level consistency rate.

[0326] [Table 7]

[0327] [Table 7-1] Analysis results using correlation evaluation criteria 1

[0328]

[0329] [Table 7-2] Analysis results using correlation evaluation criteria 2

[0330]

[0331] [Table 8]

[0332]

[0333] Example 4 Determination of FIX activity level

[0334] FIX activity was determined for 8 samples that were judged as Other (FVIII>40%) but FIX-deficient. The template samples used were the template samples in Table 9. The parameter group used was the parameter group A-1 obtained in Example 1, and the correlation evaluation was performed using the correlation evaluation criterion 1 of Example 3. The consistency rate of FIX activity level and the consistency rate of FIX deficiency were calculated by the same steps as in Example 2 (2). The evaluation results are shown in Table 10. The FIX activity level of the sample can be determined with a high consistency rate.

[0335] [Table 9]

[0336] Composition of template specimen

[0337]

[0338] Specimens with other factors: Plasma lacking coagulation factors other than FIX, plasma with heparin added, and LA-positive plasma

[0339] [Table 10]

[0340] [Table 10] Analysis results using parameter group A-1

[0341]

[0342] Example 5 Determination of FVIII Activity or Abnormality

[0343] (1) Test blood sample and template sample

[0344] As the blood samples to be tested, 46 samples of plasma from patients with reduced FVIII activity or FIX activity were used. The 46 samples consisted of 30 samples of FVIII deficiency (10 samples of severe cases (FVIII < 1%), 10 samples of moderate cases (FVIII = 1-5%), and 10 samples of mild cases (FVIII = 5-40%)), 1 sample of FVIII > 40% (Other), and 15 samples of FIX deficiency (Other).

[0345] The template specimen uses mixed plasma in which commercially available coagulation factor-deficient plasma and LA plasma or normal plasma are mixed in various proportions, and FVIII-added plasma in which a FVIII preparation is added to commercially available FVIII-deficient plasma. Coagulation factor-deficient plasma and LA plasma use factor VIII-deficient plasma, factor IX-deficient plasma, factor V-deficient plasma, factor X-deficient plasma, factor XI-deficient plasma, factor XII-deficient plasma, prekallikrein-deficient plasma, and lupus anticoagulant-positive plasma (all manufactured by George King Bio-Medical, Inc.). The FVIII preparation uses the genetically recombinant coagulation factor VIII preparation Advate (manufactured by Shire Japan). As normal plasma, normal mixed plasma in which each factor concentration is regarded as 100% is used. Normal plasma is mixed with each coagulation factor-deficient plasma in various proportions to prepare mixed plasma with factor concentrations of 0.25%, 0.5, 0.75%, 1%, 2.5%, 5%, 10%, 25%, and 50%, respectively. In addition, FVIII preparations were added to FVIII-deficient plasma to prepare FVIII-added plasma with FVIII concentrations of 0.625%, 1.25%, 2.5%, 5%, 10%, 20%, 40%, 80%, and 160%. In addition, FVIII preparations were added to another FVIII-deficient plasma to prepare FVIII-added plasma with FVIII concentrations of 0.3%, 0.6%, 1%, 2%, 4%, 8%, 16%, 32%, 64%, and 128%. A total of 143 template samples were prepared by the above steps, including 59 samples with abnormal FVIII activity, 80 samples with normal FVIII activity but low other coagulation factors, and 4 samples with LA positive. The FVIII activity levels of the 59 samples with abnormal FVIII activity belonged to any of severe hemophilia A (FVIII < 1%), moderate hemophilia A (FVIII = 1-5%), mild hemophilia A (FVIII = 5-40%), and other (FVIII > 40% is Other). The remaining 84 samples were classified as "Other" because their FVIII activity was not abnormal.

[0346] In this embodiment, all the samples to be tested are samples from patients with FVIII deficiency (hemophilia A) or samples from patients with FIX deficiency (hemophilia B). On the other hand, the template samples are prepared based on commercially available factor-deficient plasma and LA-positive plasma without using samples from patients with hemophilia A or hemophilia B. By such a sample composition, in this embodiment, compared with Example 2, conditions are set that make it difficult to correctly determine the state of the coagulation factor of the sample to be tested. The composition of the sample to be tested and the template sample used in this embodiment is shown in Table 11.

[0347] [Table 11]

[0348] Composition of the specimen

[0349]

[0350] Composition of template specimen

[0351]

[0352] The coagulation reaction curves of each test sample and template sample were obtained according to the procedure of Example 1 (1). The distribution of FVIII activity and APTT of the test sample and template sample is shown in Fig.18 .

[0353] (2) Creation of parameter groups

[0354] For each specimen, an uncorrected primary curve, an uncorrected secondary curve, a corrected primary curve, and a corrected secondary curve were calculated from the coagulation reaction curve. For each curve, 10 operation target regions based on 10 operation target region values ​​S (5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, and 90% of the maximum height of the curve) were extracted, and parameters representing each operation target region were obtained. In addition, the maximum value of the curve and the time until it was reached (Vmax, RVmax, VmaxT, Amax, RAmax, AmaxT) were obtained as the previous parameters. The obtained parameters are shown in Table 12.

[0355] [Table 12]

[0356]

[0357] (3) Determination of FVIII activity or abnormality of the test sample using a parameter group

[0358] (3-1) Judgment using a single parameter

[0359] The parameter group is composed of the parameters shown in Table 12. When using parameters that characterize the operation target area, a set of the same parameters extracted from 10 operation target areas based on 10 operation target area values ​​(x = 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% and 90%) is used as the parameter group. For example, when using the parameter "vHx", the set of [vH5%, vH10%, vH20%, vH30%, vH40%, vH50%, vH60%, vH70%, vH80%, vH90%] is used as the parameter group. When using conventional parameters, the same parameter group as the comparative example of Example 2 is used.

[0360] By using the regression analysis of the parameter group, the FVIII activity or abnormality of the test specimen is determined. A regression analysis is performed between the test parameter group obtained from the test specimen and the corresponding template parameter group obtained from each template specimen. The template specimen whose slope of the linear regression equation obtained in the regression analysis is within 1±0.15 and the correlation coefficient of the linear regression equation is greater than 0.90 is extracted. The template specimen with the largest correlation coefficient among the extracted template specimens is selected. When there are multiple specimens with the same correlation coefficient, the template specimen whose slope of the regression equation is closer to 1 is selected. The state of FVIII activity of the selected template specimen (severe hemophilia A (FVIII <1%), moderate (FVIII = 1-5%) and mild (FVIII = 5-40%) or other (Other)) is determined as the state of FVIII activity of the test specimen. Based on the determination results of all the test specimens, the consistency rate of FVIII deficiency and the consistency rate of FVIII activity level are calculated by the same steps as in Example 2.

[0361] The parameter groups used and the obtained FVIII deficiency consistency rate and FVIII activity level consistency rate are shown in Tables 13 and 14. The parameter with the largest FVIII deficiency consistency rate (63.0%) is the parameter pHx of the secondary curve. The parameter with the largest FVIII activity level consistency rate (76.1%) is the parameter mTx of the secondary curve. The FVIII deficiency consistency rate is not highly correlated with the FVIII activity level consistency rate. The FVIII deficiency consistency rate when using the previous parameters (combination of VmaxT, AmaxT, Vmax, Amax) was 52.2%.

[0362] [Table 13]

[0363]

[0364] [Table 14]

[0365]

[0366] (3-1) Determination of using combined parameters

[0367] A combination parameter group is formed by combining a plurality of parameters representing the operation target area shown in Table 12. Two or more sets of the same parameters extracted from 10 operation target areas based on 10 operation target area values ​​(x = 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% and 90%) are combined and used as a parameter group. For example, when a combination of parameters "vT" and "vB" is used, a set of [vT5%, vT10%, vT20%, vT30%, vT40%, vT50%, vT60%, vT70%, vT80%, vT90%] and a set of [vB5%, vB10%, vB20%, vB30%, vB40%, vB50%, vB60%, vB70%, vB80%, vB90%] are combined and used as a parameter group.

[0368] The combination parameter group with a high FVIII deficiency consistency rate and the obtained FVIII deficiency consistency rate and FVIII activity level consistency rate are shown in Tables 15 and 16. The results when two parameters are combined are shown in Table 15, and the results when three parameters are combined are shown in Table 16. Table 16 also records the results of the parameter group (pNs_pNe_vTB) with the largest FVIII activity level consistency rate.

[0369] [Table 15]

[0370]

[0371] [Table 16]

[0372]

[0373] The results of FVIII activity level determination for the parameter groups that brought high FVIII deficiency consistency rate or FVIII activity level consistency rate in the above (3-1) and (3-2) are shown in Table 17. As the number of parameter types used increases, it is found that both the FVIII deficiency consistency rate and the FVIII activity level consistency rate tend to increase. In addition, these results indicate that the parameters associated with the quadratic curve are useful for determination.

[0374] [Table 17]

[0375]

[0376]

[0377]

[0378] Example 6 Determination of FVIII activity or abnormality based on different determination criteria

[0379] (1) Methods

[0380] Using the samples used in Example 5, a primary regression analysis was performed between the test parameter group and the template parameter group by the same procedure as in Example 5. Next, the state of FVIII activity of the test sample was determined according to the following different determination criteria.

[0381] Criteria 1:

[0382] As in Example 5, the state of FVIII activity of the template sample with the highest correlation coefficient among the template samples whose slope of the linear regression equation is within 1±0.15 and whose correlation coefficient of the regression equation is greater than 0.90 is determined as the state of FVIII activity of the test sample. If there is no template sample that meets the conditions of the slope and correlation coefficient of the linear regression equation, the test sample is determined as Other.

[0383] Criteria 2 (most selected):

[0384] Extract the five template specimens with the highest correlation coefficient among the template specimens whose slope of the linear regression equation is within 1±0.15 and whose correlation coefficient of the regression equation is greater than 0.90. The state of FVIII activity found with the highest frequency in these five specimens is determined as the state of FVIII activity of the specimen to be tested. When the same number of specimens of different states exists, the more severe state is determined as the state of the specimen to be tested. When there is no template specimen that meets the conditions of the slope and correlation coefficient of the above linear regression equation, the specimen to be tested is determined as Other.

[0385] Criteria 3 (two-stage selection method):

[0386] Extract the five template specimens with the highest correlation coefficient from the template specimens whose slope of the linear regression equation of specimens from hemophilia A patients (severe, moderate and mild) is within 1±0.15 and the correlation coefficient of the regression equation is greater than 0.90. When there are less than five template specimens that meet the conditions of the slope and correlation coefficient of the linear regression equation, the insufficient number is recorded as ND (refer to Table 18). Calculate the total number of these five hemophilia A patients (severe [L1]: FVIII <1%, moderate [L2]: FVIII = 1-5% and mild [L3]: FVIII = 5-40%) and the total number of others (Other and ND). When the total number of hemophilia A patients is greater, the state (severe, moderate or mild) found with the highest frequency is determined as the state of the specimen to be tested. When there are the same number of specimens of different states, the more severe state is determined as the state of the specimen to be tested. When the other total counts are greater, the state of the sample under test is determined to be Other.

[0387] An example of the determination procedure is shown in Table 18. <1> The FVIII activity of the template sample of is consistent with the judgment result in judgment criterion 1. The FVIII activity of the template sample that accounts for the largest number is consistent with the judgment result in judgment criterion 2. If the total number of L1 to L3 in the template sample is larger, judgment criterion 3 is any one of L1 to L3, and if the total number of Other and ND is larger, judgment criterion 3 is Other.

[0388] [Table 18]

[0389]

[0390] L1: FVIII=<1%, L2: FVIII=1-5%, L3: FVIII=5-40%

[0391] (2)Judgment

[0392] From the 55 parameters representing the operation object area shown in Table 12, 3 parameters are arbitrarily combined to form 26235 combination parameter groups. Using each combination parameter group, a regression analysis used between the tested parameter group and the template parameter group is performed, and then the state of FVIII activity of the tested specimen is determined according to judgment criteria 1 to 3. The FVIII deficiency consistency rate or the FVIII activity level consistency rate is calculated by the same steps as in Example 2. The average (average consistency rate) of the FVIII deficiency consistency rate or the FVIII activity level consistency rate is further calculated.

[0393] Table 19 shows examples of the FVIII deficiency consistency rate, FVIII activity level consistency rate, and average consistency rate (also collectively referred to as consistency rate) determined according to each judgment criterion.

[0394] [Table 19]

[0395]

[0396] Table 20 shows the number of combined parameter groups that achieve the consistency level. The bottom line of Table 20 shows the maximum value of the consistency rate under each criterion. The FVIII lack consistency rate is a maximum of 78.3% under any criterion. The number of combined parameter groups that meet the maximum consistency level (more than 75% and less than 80%) is 12 under criterion 1 and 17 under criterion 2 and 3. The FVIII activity level consistency rate is a maximum of 91.3% under any criterion. The number of parameter groups that meet the maximum consistency level (more than 90% and less than 95%) is 1 under criterion 1 and 3, and 2 under criterion 2. The maximum value of the average consistency rate is 81.5% under criterion 1 and 84.8% under criterion 2 and 3. The number of parameter groups that meet the maximum consistency level (more than 80% and less than 85%) is 9 under criterion 1 and 13 under criterion 2 and 3.

[0397] [Table 20]

[0398]

[0399] Example 7 Determination of FVIII activity or abnormality based on different thresholds

[0400] The same steps as in Example 6 are used, according to judgment criteria 1 to 3, but the allowable range of the slope of the linear regression equation and the threshold value of the correlation coefficient are changed to determine the state of FVIII activity of the test subject. The parameter group uses the combined parameter group pTW_vTs_vW that shows the largest FVIII deficiency consistency rate and FVIII activity level consistency rate in Example 5. The slope of the linear regression equation is changed in stages from 1±0.05 to 1±0.25 (i.e., the allowable range is 0.05 to 0.25). In addition, the threshold value of the correlation coefficient is changed in stages from >0.75 to >0.98. The FVIII deficiency consistency rate and the FVIII activity level consistency rate under each condition are calculated. The results are shown in Figures 19 to 21 .

Claims

1. A method for analyzing a blood sample, comprising: Obtain a waveform related to the coagulation rate or coagulation acceleration of a sample formed by mixing a blood sample to be tested and a coagulation time measurement reagent, Extract a plurality of parameters characterizing the waveform related to the coagulation rate or coagulation acceleration, and Based on the plurality of parameters, determine the activity level or activity abnormality of the coagulation factor in the blood sample to be tested, The plurality of parameters include a plurality of parameters respectively characterizing a plurality of operation target regions of the waveform related to the coagulation rate, or include a plurality of parameters respectively characterizing a plurality of operation target regions of the waveform related to the coagulation acceleration, or include a combination thereof, The plurality of parameters include one or more selected from the following parameters: The weighted average time vT, weighted average height vH, peak width vB, weighted average peak width vW, B flatness rate vAB of the weighted average height, W flatness rate vAW of the weighted average height, B time rate vTB of the weighted average time, W time rate vTW of the weighted average time, average time vTa, average height vHa, B flatness rate vABa of the average height, W flatness rate vAWa of the average height, region start time vTs, region end time vTe, region center time vTm, region time width vTr, main peak start time vNs, main peak end time vNe, and main peak width vN of a plurality of operation target regions of the waveform related to the coagulation rate, The weighted average time pT, weighted average height pH, peak width pB, weighted average peak width pW, B flatness rate pAB of the weighted average height, W flatness rate pAW of the weighted average height, B time rate pTB of the weighted average time, W time rate pTW of the weighted average time, main peak start time pNs, main peak end time pNe, and main peak width pN of a plurality of operation target regions of the positive peak of the waveform related to the coagulation acceleration, and The weighted average time mT, weighted average height mH, peak width mB, weighted average peak width mW, B flatness rate mAB of the weighted average height, W flatness rate mAW of the weighted average height, B time rate mTB of the weighted average time, W time rate mTW of the weighted average time, main peak start time mNs, main peak end time mNe, and main peak width mN of a plurality of operation target regions of the negative peak of the waveform related to the coagulation acceleration.

2. The analysis method according to claim 1, wherein When the waveform related to the coagulation rate is set to F(t), and the times when F(t) is a specified value x are set to t1 and t2, the operation target region is a region satisfying F(t)≥x, where t is time, t1 < t2, and the vT and vH are represented by the following formulas, Here, F(t), t1, and t2 have the same definitions as the F(t), t1, and t2. When the data fraction from F(t1) to F(t2) is set to n, the vTa, vHa, and vTm are respectively represented by the following formulas, The vB is the time length of F(t)≥x from t1 to t2, The vW is the time length of F(t)≥vH from t1 to t2, The vTs and vTe are t1 and t2 respectively, The vTr is the time length from vTs to vTe, The vNs is the maximum time among the times in the operation object region that are less than the maximum value of F(t) and the time when F(t) = x, The vNe is the minimum time among the times in the operation object region that are greater than the maximum value of F(t) and the time when F(t) = x, The vN is the time length from vNs to vNe, The vAB represents the ratio of the vH to the vB, The vAW represents the ratio of the vH to the vW, The vTB represents the ratio of the vT to the vB, The vTW represents the ratio of the vT to the vW, The vABa represents the ratio of the vHa to the vB, The vAWa represents the ratio of the vHa to the vW.

3. The analysis method according to claim 1, wherein When the waveform related to the solidification acceleration is set as F'(t), and the times when F'(t) is the specified value x are set as t1 and t2, the operation object region is the region satisfying F'(t) ≥ x, where t is time, t1 < t2, and the pT and pH are represented by the following formula, Here, The pB is the time length of F'(t) ≥ x from t1 to t2, The pW is the time length of F'(t) ≥ pH from t1 to t2, The pNs is the maximum time among the times in the operation object region that are less than the maximum value of F'(t) and the time when F'(t) = x, The pNe is the minimum time among the times in the operation object region that are greater than the maximum value of F'(t) and the time when F'(t) = x, The pN is the time length from pNs to pNe, The pAB represents the ratio of the pH to the pB, The pAW represents the ratio of the pH to the pW, The pTB represents the ratio of the pT to the pB, The pTW represents the ratio of the pT to the pW.

4. The analysis method according to claim 1, wherein When the waveform related to the solidification acceleration is set as F'(t), and the times when F'(t) is the specified value x are set as t1 and t2, the operation object region is the region satisfying F'(t) ≤ x, where t is time, t1 < t2, and the mT and mH are represented by the following formula, Here, The mB is the time length of F'(t) ≤ x from t1 to t2, The mW is the time length of F'(t) ≤ mH from t1 to t2, The mNs is the maximum time among the times in the operation object region that are less than the minimum value of F'(t) and the time when F'(t) = x, The mNe is the minimum time among the times in the operation object region that are greater than the minimum value of F'(t) and the time when F'(t) = x, The mN is the time length from mNs to mNe, The mAB represents the ratio of the mH to the mB, The mAW represents the ratio of the mH to the mW, The mTB represents the ratio of the mT to the mB, The mTW represents the ratio of the mT to the mW.

5. The analysis method according to any one of claims 2 to 4, wherein The specified value x is 0.5 - 99% of the maximum value of the F(t), or 0.5 - 99% of the maximum value of the positive peak of the F'(t), or 0.5 - 99% of the minimum value of the negative peak of the F'(t).

6. The analysis method according to any one of claims 1 to 4, wherein The plurality of operation target regions are 5 to 20 different regions.

7. The analysis method according to any one of claims 1 to 4, wherein The determination includes: comparing the plurality of parameter groups of the test blood sample with parameter groups corresponding to a plurality of template blood samples, and determining the activity level or activity abnormality of the coagulation factor in the test blood sample based on the result of the comparison; The template blood sample is a blood sample whose activity level or the presence or absence of activity abnormality of the coagulation factor is known.

8. The analysis method according to claim 7, wherein: The comparison includes obtaining correlations between the plurality of parameter groups of the test blood sample and the parameter groups corresponding to the plurality of template blood samples.

9. The analysis method according to claim 8, wherein: The determination includes: selecting a template blood sample whose correlation satisfies a predetermined condition, and The activity level or activity abnormality of the coagulation factor in the selected template blood sample is determined as the activity level or activity abnormality of the coagulation factor in the test blood sample.

10. The analysis method according to any one of claims 1 to 4, wherein The coagulation factor is coagulation factor VIII or coagulation factor IX.

11. The analysis method according to claim 10, wherein: The determination includes performing determination on a test blood sample from a hemophilia A patient.

12. The analysis method according to claim 10, wherein: The determination includes determining a blood sample from a severe, moderate, or mild hemophilia A patient.

13. The analysis method according to claim 10, wherein: The method further comprises a second determination step of determining the activity level or activity abnormality of the coagulation factor IX in the test blood sample determined to be normal in the coagulation factor VIII. The second determination step includes: comparing the set of the plurality of parameters of the test blood sample with the set of parameters corresponding to a plurality of template blood samples whose activity levels or the presence or absence of activity abnormalities of coagulation factor IX are known, and Based on the result of the comparison, the activity level or activity abnormality of the blood coagulation factor IX in the test blood sample is determined.

14. The analysis method according to claim 13, wherein: The determination includes performing determination on a blood sample from a hemophilia B patient.

15. The analysis method according to claim 13, wherein: The determination includes determining a blood sample from a severe, moderate, or mild hemophilia B patient.

16. A program for performing the blood sample analysis method according to any one of claims 1 to 15.

17. An apparatus for performing the blood sample analysis method according to any one of claims 1 to 15.